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Abstract 
Myrmecia pilosula (Jack Jumper) is an endemic Australian ant whose sting is a frequent 
cause of insect allergy in parts of South-Eastern and South-Western Australia, causing 
severe anaphylaxis in approximately 3% of the population. The venom of Myrmecia pilosula 
ant contains IgE-binding components frequently responsible for the severe anaphylactic 
reactions in humans. A treatment modality based on purified M. pilosula ant venom extract 
has been developed by members of the Tasmanian Jack Jumper Allergy Program. The 
treatment, known as Jack Jumper Ant Venom Immunotherapy (JJA VIT), was proven to 
reduce the risk of severe anaphylaxis in sensitized patients and improve patients’ Quality of 
Life. However, the current treatment is associated with frequent adverse reactions and long 
treatment duration. As the principal Pharmacist and Quality Manager responsible for the 
manufacture of JJA VIT products, it is my primary interest to continuously improve the 
quality, safety and efficacy of this important life-saving treatment, which is uniquely 
Australian. 
My review of allergic reactions to the venom of stinging ants (as detailed in Chapter 1 and 
Chapter 2) illustrated the burden and impact of M. pilosula venom allergy in Australia and 
highlights aspects of M. pilosula venom and JJA VIT that warrant further scientific 
investigations, which consequently shaped the objectives and research questions of this PhD 
thesis. 
This research has two general objectives that were aimed to advance this treatment 
modality, and I have performed several interconnected studies to answer my research 
questions (Chapter 3). My first research objective was to improve the quality of the JJA VIT 
produced. In Chapter 4 I explored the intrinsic and extrinsic factors that could influence 
batch-to-batch consistency and quality of pharmaceutical grade Jack Jumper ant venom 
(JJAV) extracts in the form of Active Pharmaceutical Ingredients, particularly with respect to 
their IgE-binding components and activities. In this analysis, I found that components of the 
venom with molecular weight of >20 kDa are significantly affected by elevated temperature 
above 40oC. Notably, these venom components are capable of binding to IgE and they were 
of unknown identity, and their identities are revealed in Chapter 5. I analysed the proteome 
xviii 
and allergenome of JJAV separated using a combination of various gel electrophoresis and 
liquid chromatography techniques. To help divulge the identity of novel JJAV components 
capable of binding IgE, I employed a tandem Mass Spectrometry technique. From this study, 
I identified 17 novel JJAV proteins, including two glycoproteins, and confirmed the presence 
of four known Myr p and pilosulin peptides in JJAV. Most of the newly identified IgE-binding 
proteins were enzymes, including phospholipase A2, hyaluronidase, arginine kinase, and 
dipeptidyl peptidase IV.  
My second research objective was to improve the safety and efficacy of JJA VIT. For this 
purpose, I analysed the response of subjects undergoing JJA VIT with respect to their IgE-
binding recognition to JJAV components pre-treatment and I correlated this information 
with treatment tolerability and efficacy. I subsequently linked this clinical data with the 
various JJAV components identified via tandem Mass Spectrometry and report my results in 
Chapter 5. In this study, I established correlations between recognition of certain IgE-
binding bands with JJAV-specific IgE titre by ImmunoCAP, intradermal test threshold, and 
treatment-related issues. Finally, driven by the relative difficulty in obtaining pharmaceutical 
grade JJAV extracts and the recent increase in demand to treat patients with JJAV allergy 
within Tasmania and interstate, I explored the safety and efficacy of treatment with low-
dose JJA VIT using Advax™ adjuvant. In order to enable a clinical trial using this novel 
combination product, I performed fundamental pharmaceutical and immunological studies. 
In Chapter 6 I report the physicochemical and microbiological stability and murine 
immunogenicity of low-dose JJA VIT in combination with Advax adjuvant. I observed that JJA 
VIT formulated with Advax is both physicochemically and microbiologically stable for at least 
2 days when stored at 4 and 25oC, with a trend for an increase in allergenic potency 
observed beyond 2 days of storage. Importantly, JJA VIT formulated with Advax significantly 
increased the production of JJAV-specific IgG, consistent with a JJAV antigen-sparing effect 
of the adjuvant, which supports the use of Advax adjuvant with JJA VIT in future clinical 
trials. 
Overall, my PhD project has advanced our knowledge on the pharmaceutical and 
immunological aspects of JJA VIT and provides a robust platform to enhance the quality, 
safety and efficacy of this life-saving treatment modality. 
1 
Part I:  INTRODUCTION 
2 
Chapter 1: Systemic anaphylactic reactions to the venoms of stinging ants 
and its management 
1. Overview
Hymenoptera venom allergy is characterised by systemic anaphylactic reactions that 
occur in response to stings from members of the Hymenoptera order (1). Stinging by social 
Hymenoptera such as ants, honeybees and vespids, is one of the 3 major causes of 
anaphylaxis along with food and drug exposure (2, 3), and it accounts for up to 43% of 
anaphylaxis cases and 20% of anaphylaxis-related fatalities (4, 5). The prevalence of 
systemic anaphylactic reactions to Hymenoptera stings, predominantly by honeybees and 
Vespula species, ranges from 0.5% to 7.5% in adult and up to 3.4% in children (6-8). Despite 
their recognition as being of considerable public health significance (9), stinging ant venoms 
are relatively unexplored in comparison to other animal venoms and may be overlooked as 
a cause of venom allergy (10, 11). Indeed, the venoms of stinging ants may be the most 
common cause of anaphylaxis in ant endemic areas (12-15). A better understanding of the 
natural history of venom allergy caused by stinging ants, their venom components, and the 
management of ant venom allergy is therefore required. The following sections will provide 
a global view on allergic reactions to the venoms of stinging ants and the contemporary 
approach to diagnose and manage ant venom allergy, with emphasis on the Australian 
context. 
2. Epidemiology of ant venom allergy
Ants (order Hymenoptera, family Formicidae) are very biodiverse organisms with 21
recognized subfamilies and more than 13,000 described species (16, 17). Sixteen subfamilies 
of ants and 1900 living species have a stinging apparatus and use injected venom for 
defence against predators, prey capture, and social communication (18, 19). However, most 
stinging ants are not aggressive and rarely sting large organisms. There are about nineteen 
genera of ants that have been associated with venom allergy in humans, but only members 
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of four genera (Figure 1), namely Solenopsis spp., Myrmecia spp., Pachycondyla spp., and 
Pogonomyrmex spp. have caused anaphylactic reactions and fatalities frequently enough to 
be considered important medical problems. The risk of envenomation and anaphylactic 
reaction by a particular species of stinging ant depends on complex interactions between 
the likelihood of human contact, species aggressiveness, efficiency of the venom delivery 
apparatus and venom allergenicity (20, 21). 
 
2.1. Causative species 
2.1.1. Solenopsis spp. 
The genus Solenopsis comprises small to medium sized ants of 2 to 6 mm in length. 
They are commonly referred to as fire ants due to the fierce burning pain inflicted by their 
sting (22). There are over 60 known species of fire ants within this genus (23), but only five 
species have been associated with sting allergy. Fire ants are usually found in large colonies 
of 250,000 ants or more, and up to 600 mounds per acre may be found in heavily infested 
areas (22). Fire ants use pheromones to recruit large numbers of worker ants to attack 
intruders en masse (24), thus achieving a significant antigenic load despite their small 
individual stings. The medically important species of fire ants are S. richteri, S. invicta, S. 
aurea, S. geminata, and S. xyloni. 
S. richteri, the black fire ant, was introduced into the United States of America (USA) 
from Uruguay or Argentina by cargo vessels through the port of Mobile, Alabama, in 1918 
(25), while S. invicta, the red fire ant, was introduced to the USA from Brazil around the time 
of World War II (26). They are often referred to as Imported Fire Ant (IFA) to distinguish 
them from the native North American fire ant species, S. aurea (desert fire ant), S. geminata 
(tropical fire ant), and S. xyloni (southern fire ant). The red IFA, S. invicta has also been 
established in Asia and Australia, while the black IFA, S. richteri has been carried as far as 
Saudi Arabia (24, 27-31). The tropical fire ant, S. geminata, commonly found in Mexico, 
Central America and the Caribbean islands (32), has become a serious pest and the cause of 
ant sting allergy in Southeast Asia, United Arab Emirates, and on some Pacific islands 




Figure 1.   Schematic diagram depicting phylogenetic relationships of social Hymenoptera, with an emphasis on stinging ants frequently linked 
to anaphylactic reactions and death in humans
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2.1.2. Myrmecia spp. 
The genus Myrmecia is one of the most primitive subfamilies of ants, and is widely 
distributed in and virtually endemic to Australia, with only one species found in New 
Caledonia (36, 37). A species of Myrmecia ants, M. gulosa, was among the earliest 
Australian insects to be discovered by Joseph Banks and Daniel Solander at Botany Bay in 
1770 when they were on shore from Captain Cook’s “Endeavour” (21). Myrmecia spp. are 
highly aggressive ants (38, 39), characterised by the prominent pair of powerful mandibles 
and large eyes that enable them to use visual cues to navigate (40). There are 89 recognized 
species within this genus, which can be broadly divided into two groups based on their 
morphological characteristics (36, 41). The first group comprises ants commonly known as 
“bulldog ants”, “bull ants”, “bulljoe ants”, “giant bull ants”, or “inchman ants” (Figure 2). 
Species in this group all share a large body length between 20 to 30 mm (41). The typical 
species in this group is exemplified by the “bulldog ant”, M. pyriformis, which is brown in 
colour and is common to open sclerophyll woodland in South-Eastern Australia (42), M. 
gulosa, a slender ant with long legs and a variety of colours (41, 43), and the “inchman ant”, 
M. forficata, with a purple-brown body and black abdomen that predominates in Tasmania 
(41). 
The second group includes smaller-sized ants, typically 10 to 12 mm in length, which are 
commonly known as jumper ants (Figure 2). The most notable species and an archetype for 
this group is M. pilosula, an exceptionally aggressive stinging ant with highly developed 
vision that is attracted to movement (20, 40). M. pilosula has a jet black body and yellow or 
orange mandibles and leg tips. These ants move in short jerks and jumps, leading to the 
names “jumper ant”, “hopper ant”, “jumping jack”, “black jumper”, “jackie jumper”, and 
“jack jumper” (11, 44). M. pilosula is a “species complex”, comprised of several closely 
related sibling species with subtle morphological differences (45-47). Components of the 
species complex have been recently reviewed, illustrated and keyed; the six known 
members of the complex are M. banksi sp. nov., M. croslandi Taylor 1991, M. haskinsorum 
sp. nov., M. imaii sp. nov., M. imparternata sp. nov, and M. pilosula Fr. Smith 1858 (44). M. 
pilosula form small colonies of 100 to 1000 ants and their nests range from a single hole to 
mounds up to a meter in diameter with multiple entrances (Figure 2), typically surrounded 
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by a scattering of fine gravel (11, 20, 48). M. pilosula is found in sandy soiled areas starting 
from north of Brisbane through to the higher altitude and rural areas of South-Eastern 
Australia and west to the vicinity of Denmark in Western Australia (42, 43, 49). Several ant 
species from this genus are an important cause of anaphylactic sting reactions in Australia 
(21, 41). Allergy is common, particularly to the venom of M. pilosula in Tasmania, regional 
Victoria, the Adelaide Hills and southern NSW (11, 21, 48, 50). Unlike the massive ant 
attacks typical of IFA, single or few stings from M. pilosula are sufficient to cause 
anaphylactic reactions in humans (14). 
 
 
Figure 2.   Pictures of some Myrmecia ant species 
Panel A: large bulldog ant, Myrmecia pyriformis, and a smaller jack jumper ant, Myrmecia pilosula. 
Panel B: A Myrmecia ants’ nest showing a single entrance. Panel C: A jumper ant, Myrmecia 
nigrocincta and bulldog ants of the Myrmecia gulosa species group. Photographs are courtesy of 
Professor Simon Brown. 
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2.1.3. Pachycondyla spp. 
The ants of the genus Pachycondyla [now reclassified as Neoponera spp. (51)] originate 
from the neotropics, but have been spread to numerous locations by commerce, including 
to the South-Eastern USA (52-54). The genus comprises approximately 200 species, most of 
which appear to be predators, which subdue their prey with their venom (55). Two species, 
P. chinensis and P. sennaarensis, have been recurrently reported to cause anaphylactic sting 
reactions in humans (56-61), while another species, P. goeldii, has been associated with ant 
sting anaphylaxis in a single case report (62). 
P. chinensis (Chinese or Asian needle ant) originates from Far East Asia, but is now 
widely distributed throughout Asian-Pacific countries (53, 63). P. chinensis are 4 to 6 mm in 
length, with a shiny brownish-black body, orange-brown legs and a well-defined stinger (52). 
Similar to M. pilosula, P. chinensis is also a species complex (64). P. chinensis colonies are 
composed of a few hundred workers, and nests tend to be found in damp areas near 
mature forest, within rotten wood, or in old wooden houses (60, 65). Although not an 
aggressive species, P. chinensis is known to have a sting that results in sharp, low-pain 
intensity that persists for 30 minutes or more (23, 65-67). 
P. sennaarensis (samsum or sword ant) has a black and relatively slender 4 to 6 mm 
long body and is widely distributed throughout the African tropics, Arabian peninsula and 
Southern Iran (54, 66, 68). Colonies of P. sennaarensis typically contain several thousand 
workers in underground nests approximately one meter deep (55, 69). P. sennaarensis 
requires an environment with high humidity, so they are commonly found around human 
settlements with a strong presence in gardens and buildings. P. sennaarensis is an 
“opportunist” ant; in its natural habitat it has a mainly granivorous diet during the dry 
season and feeds on animal prey during the rainy season, but in urban areas the ants 
scavenge on human food refuse (54, 66, 70). P. sennaarensis has a reputation for its 
aggressiveness and extremely painful sting, with pain that can persist for up to 4 hours (34, 





2.1.4. Pogonomyrmex spp. 
Certain members of the genus Pogonomyrmex have been reported to cause ant sting 
anaphylaxis in the USA. Commonly referred to as the harvester ant, they have large 
mandibles to collect and feed on seeds from their native habitat (72, 73). They are 5 to 9 
mm in length and are reddish to blackish in colour (74). Harvester ants usually construct 
their nests in the sand or soil, and may be more than 6 meters deep, containing large 
colonies of more than 20,000 ants (75). The genus comprises over seventy species and are 
found in arid grasslands and deserts of North and South America (76). Three species, P. 
barbatus (red harvester ant), P. maricopa (Maricopa harvester ant), and P. rugosus (rough 
harvester ant) have been reported to cause anaphylactic sting reactions in humans, 
particularly around the South-Western North American desert (72, 73, 77). Although less 
aggressive than members of the genus Solenopsis, harvester ants also sting en masse and 
the sting of these ants has long been recognized for their extreme painfulness that may last 
for up to 24 hours (23, 74, 76, 78). The pain has been described as “ripping muscles or 
tendons” and like “turning a screw in the flesh” (18). The venom causes localized sweating 
and piloerection at the sting site and is accompanied by pain and tenderness in nearby 
lymph nodes (79). It is these properties that have earned them the reputation of being 
dangerous adversaries to humans (9). 
 
2.1.5. Other ant species associated with allergic reactions 
In addition to the four genera of stinging ants of medical importance described above, 
at least 16 other species of ants have also been associated with allergic reactions in humans 
(Table 1). One of these ants, Rhytidoponera metallica, is a frequent cause of ant sting 
anaphylaxis in Queensland (41, 80-82), with some cases have also been reported from 
country New South Wales (41, 83). R. metallica is a native Australian ant species of the 
subfamily Ectatomminae (63). It is an omnivorous diurnal predator, which feeds on insects 
and invertebrates (84), and forager of seeds and honeydew (85). The worker ant is 5 to 7 
mm long with variation in a metallic colour of green, purple, red and violet (85). R. metallica 
is widely distributed throughout Australia (42). It mainly inhabits open and moderately 
wooded areas, including metropolitan parks and gardens (85). 
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Table 1.   Other ant species reported to cause allergic reactions in humans 
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2.2. Incidence and prevalence of ant sting allergy 
2.2.1. Solenopsis spp. 
Stings by the IFA are a major cause of systemic allergic reactions in South and Central 
America as well as in South-Eastern USA (33, 100). Isolated cases of anaphylactic sting 
reactions due to IFA have also been reported in Australia, Canada, Saudi Arabia, Spain and 
Switzerland (24, 31, 101-103). In heavily infested areas in Southern USA, sting attack rates 
range from 13% to 58% of the population per year with the highest attack rates occurring 
between April and September (22, 26, 104). In these endemic areas, the incidence of 
systemic anaphylaxis due to IFA stings exceeds that of other species of Hymenoptera (9, 12). 
Rhoades et al. estimated nearly four new cases of IFA envenomation per 100,000 
population per year (105). In one survey of 29,205 physicians, it was reported that 20,755 
patients per year were treated for IFA sting reactions, of whom 413 (2%) had life-
threatening anaphylaxis (106). Other surveys reported that 0.6% to 16% of those stung by 
IFA developed anaphylaxis (107). Over 80 fatal and two near-fatal anaphylactic reactions 
caused by IFA stings have been reported (107-109). While the overwhelming majority of 
allergic sting reactions to fire ants are caused by IFA, cases of systemic allergic reactions 
caused by the less common species of fire ants, S. aurea, S. geminata and S. xyloni have also 
been described in India, Indonesia, Thailand and USA (32, 35, 63, 77, 110-113). 
 
2.2.2. Myrmecia spp. 
Myrmecia spp. is the predominant cause of ant sting allergy in Australia, implicated in 
89% anaphylaxis cases due to ant stings (41). The prevalence of systemic allergic reaction to 
the venom of Myrmecia ants is 0.8% in Queensland, 2.4% in regional Victoria and 2.7% in 
Tasmania (13, 50, 81). Nationally, 60.8% of the 347 hospitalised cases involving ant sting 
allergy between 2002 and 2005 have been attributed to Myrmecia spp. (114). The jumper 
ant M. pilosula is the principal cause, accounting for 57% of all of ant sting anaphylaxis 
incidents in one large nationwide study (41). The largest number of stings by M. pilosula 
resulting in anaphylaxis involved residents of Victoria (37.5%) and Tasmania (26.5%) (114). 
In Western Australia the bulldog ants, M. gratiosa and M. nigriscapa, and a jumper ant, M. 
ludlowi, have been responsible for 10 cases of ant sting anaphylaxis (82). In Tasmania, 
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where 12% of the population is exposed to M. pilosula stings every year (13), it accounts for 
15.4% of the total allergic reactions and cases of anaphylaxis, and between 21% to 25% of 
anaphylaxis cases treated with adrenaline at the Emergency Department of the Royal 
Hobart Hospital, the only public teaching hospital in Southern Tasmania (11, 115). Around 
1% of the population in Tasmania is at risk of severe and potentially life-threatening 
anaphylactic reactions to M. pilosula stings (13). 
Fatal anaphylaxis from Myrmecia spp. stings has also been documented. Three ant-sting 
related fatalities were recorded in NSW in 1931 and one fatality was recorded from 
Tasmania in 1963 (116, 117). Additionally, six documented cases of ant sting-related 
fatalities were attributed to M. pilosula, M. pyriformis, or M. forficata in the Australian 
Coronial records between 1980 and 1999; all the deceased were living in either NSW or 
Southern Tasmania (11, 14). Examination of the National Mortality Database maintained by 
the Australian Institute of Health and Welfare between January 1997 and December 2005 
shows 20 cases of Hymenoptera sting-induced anaphylaxis fatalities, with 30% of the 
fatalities attributed to Myrmecia spp. and arthropods other than honeybees and vespids 
(118). In another study, using data extracted from the Australian National Coronial 
Information System database, a total of 34 deaths due to Hymenoptera stings or tick bites 
were recorded between January 2000 to December 2013, of which 6% (n=2) were caused by 
ant-sting related anaphylaxis (119, 120). Taken together, the incidence of fatalities due to 
ant sting anaphylaxis in Australia occurred at a rate of approximately 0.01 per million 
populations per year. 
 
2.2.3. Pacycondyla spp. 
Numerous incidences of allergic sting reactions to the venom of P. chinensis have been 
reported, mostly from South Korea, but some cases from Japan and South-Eastern USA have 
also been reported (53, 56, 57, 60, 121-126). There have been multiple reports of allergic 
sting reactions caused by P. sennaarensis in Saudi Arabia, South-Eastern Iran and the United 
Arab Emirates (UAE), including five cases of fatal sting anaphylactic reactions in the UAE (34, 
58, 59, 61, 68, 127-131). A single case of ant sting anaphylaxis caused by P. goeldii was 
recently reported in Brazil (62). The proportion of the population that experienced systemic 
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allergic reactions and life-threatening anaphylactic reactions to P. chinensis stings in an ant-
endemic area of South Korea have been reported to be 2.1% and 1.2%, respectively (122), 
which is comparable to those seen in the endemic areas for IFA and Myrmecia spp. in USA 
and Australia respectively. 
 
2.2.4. Pogonomyrmex spp. 
Stings from ants of the genus Pogonomyrmex occasionally result in allergic reactions. At 
least two deaths and a single anaphylactic reaction were attributed to stings of the red 
harvester ant, P. barbatus, between 1950 and 1974 (77, 132, 133). During this period, 
harvester ant stings were also implicated in severe allergic reactions in at least 27 people in 
Texas (134). Further cases of anaphylactic reactions in four patients and large local reactions 
in another four patients caused by either P. maricopa or P. rugosus were reported in Arizona 
in 1977 (73). More recently, three cases of anaphylactic reactions by P. barbatus, P. 
maricopa and P. rugosus were reported from Arizona and Texas in the early 2000s (63, 113, 
135). The Florida harvester ant, P. badius, has a venom that appears capable of causing 
allergic reactions (see section 3 below), but anaphylactic reactions to this species have not 
been reported (136). 
 
3. Ant venom components, venom allergens and their immunological cross-reactivity 
potential 
Knowledge of the composition of ant venoms, particularly venom allergens and their 
cross-reactivity potential is a prerequisite for the accurate diagnosis and treatment of ant 
venom allergy. However, despite the rapid progress in the fields of genomics, 
transcriptomics and proteomics over the last decades, venom allergens of stinging ants 
were seldom comprehensively analysed. The limited amount of venom present in the 
venom sac of ants hinders its analysis and consequently limits the available data on ant 
venom chemistry and composition (137, 138). The currently available information shows 
that ant venoms include a complex mixture of chemicals including proteins, peptides, 
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biogenic amines, hydrocarbons and other organic molecules (9, 18, 137-139). However, only 
those venoms that contain proteins and large peptides cause allergic reactions (140). 
Compared to other Hymenoptera venom allergens, only a limited number of stinging 
ant venom allergens have been characterized and named according to the International 
Union of Immunological Societies (IUIS) criteria for allergen nomenclature (141). Under this 
system, allergens are designated according to the accepted Linnéan taxonomic name of 
their source as follows: the first three letters of the genus, space, the first letter of the 
species, space, and followed by an Arabic numeral, which is assigned to individual allergens 
in the order of their identification. Where isoallergens and variants of an allergen group 
have been identified, they are designated by suffixes of a period followed by four Arabic 
numerals. The first two numerals (01 to 99) refer to a particular isoallergen, and the two 
subsequent numerals (01 to 99) refer to a particular variant of a particular isoallergen (141). 
Additionally, allergens may also be referred to as major and minor depending on whether in 
more or less than 50% of allergic patients the corresponding allergen specific IgE can be 
detected (142). 
 
3.1. Solenopsis spp. 
The venom of IFA is composed of a 90 to 95% non-aqueous phase containing non-
allergenic piperidine alkaloids named Solenopsins, primarily of the trans stereoisomer of 
2,6-dialkylpiperidines (143-147). These alkaloids are responsible for local sting reactions and 
the development of a characteristic sterile pustule formation at the sting site (148). The 
aqueous phase of S. invicta venom contains approximately 10‒100 ng of protein per sting 
(149). Forty-six proteins with molecular weights of <10 kDa to 44 kDa have recently been 
identified in the venom of S. invicta, 21 of which are toxins. These proteins include various 
neurotoxins, myotoxin 2-like proteins, and ponericin-like peptides (150). Immunoblot 
studies identified five IgE-binding bands in S. invicta venom, two of which are major 
allergens (151). Four distinct allergenic proteins, designated Sol i 1‒4, have been isolated, 
sequenced and characterized (149, 152). 
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Sol i 1 is a major allergen in IFA venom, but comprises only 2 to 4% of the total venom 
protein (149, 153). It is a 37 kDa phospholipase A1 protein, with 35% sequence homology to 
those found in vespid venom (19, 154, 155). It contains N-linked carbohydrates, but a study 
using recombinant carbohydrate-free Sol i 1 indicated that IgE reactivity appears to be 
against protein determinants (156). Some honeybee and vespid venom-sensitized 
individuals produce IgE antibodies that cross-react with Sol i 1 (157), and as such these 
individuals may experience allergic reactions to their first IFA sting (140). 
Sol i 3 is the second major allergen in IFA venom and makes up about 15 to 25% of the 
venom protein (33). It has a molecular weight of 24 kDa and is a member of the antigen 5 
family of vespid venom (27, 153). Sol i 3 does not contain N-linked carbohydrates and 
displays 47% sequence homology to antigen 5 from vespid venom (Ves v 5) (152). However, 
the three-dimensional structure of Sol i 3 has been determined (158), and shows very little 
surface conservation relative to antigen 5 (27), which is consistent with a lack of 
immunological cross-reactivity (140). 
Sol i 2 displays the highest protein concentration in IFA venom, representing 67% of the 
total (22). It is a disulfide-linked homodimeric protein of 28 kDa (72, 159). The three-
dimensional structure of Sol i 2 suggests that it is related to pheromone-binding proteins 
(160). Sol i 4 is a monomeric protein of 13.3 kDa (100), and a member of the Sol i 2 family. 
Sol i 4 represents about 9% of the IFA venom protein and is the most basic protein 
component in IFA venom with an isoelectric point (pI) of 10.08 (107). It has about 35% 
sequence homology and one less cysteine residue than Sol i 2 monomers, which prevents 
dimerization (72, 140, 149, 159). Sol i 2 and Sol i 4 are minor allergens and neither contain 
N-linked carbohydrates (27, 153). 
The Sol 2 antigen group shows a lower degree of sequence conservation among 
different fire ant species, while the Sol 1 and Sol 3 antigen groups appear to be more 
conserved (27, 154, 161). However, studies on sera from patients allergic to the native fire 
ant species S. aurea and S. xyloni show some evidence of immunological cross-reactivity 
with the Sol i 2 and Sol r 2, suggesting that similar IgE-binding epitope(s) is/are present in 
the venom of these species (32, 162). S. richteri venom does not contain a protein 
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analogous to Sol i 4, but a homologous allergen Sol g 4 is present in the venom of S. 
geminata (27). 
 
3.2. Myrmecia spp. 
Studies on the venom components of Myrmecia spp. have been performed on M. 
pilosula, M. gulosa and M. pyriformis. The currently known composition, structure and 
function of the venoms, with a particular emphasis on the Pilosulin peptides from M. 
pilosula venom, have been subjected to an in-depth review (163) (see following chapter for 
details of the review). The venoms of M. pilosula and M. pyriformis contain phospholipase 
A2, phospholipase B, hyaluronidase, acid and alkaline phosphatases, histamine-releasing 
activities, and a heat-sensitive haemolytic factor (164-168). Analysis of M. gulosa venom 
shows the presence of 13 unique peptides named MIITX-Mg and six proteins, including a 
venom antigen 5, a venom dipeptidyl peptidase IV, a phosphatase, an esterase, and a 
hyaluronidase (169-171). Histamine has been found in all three Myrmecia venoms, with M. 
pyriformis venom containing significantly more than honeybee venom (166, 167, 170), and 
M. forficata venom is also exceedingly rich in histamine (172). Pharmacological studies on 
M. pilosula and M. pyriformis venoms showed that they are able to promote the synthesis 
of arachidonic acid metabolites (167), which is most likely related to the presence of 
phospholipase A2 in the venoms (173). In addition to their allergenic potentials, the venoms 
of Myrmecia ants are also highly toxic to mammals (23), with intraperitoneal administration 
of M. pyriformis venom in mice inducing agitation and aggressiveness, which is usually 
followed by a quiescent period before death (166). The lethal dose for 50 percent of the 
animals (LD50) for Myrmecia ant venoms compared to honeybee (Apis mellifera) venom in 
mice is shown in Table 2 below. 
Three peptides in M. pilosula venom have been recognized as allergens by the 
International Union of Immunology Societies, and are named Myr p 1, Myr p 2 and Myr p 3 
(174), and another peptide in venom is a histamine-releasing peptide Pilosulin 5 (175). Myr 
p 1 is a monomer peptide of 6067 Da (also called Pilosulin 1 and M-myrmeciitoxin-Mp1a); 
Myr p 2 is a disulfide linked heterodimer of 5608 Da (also called Pilosulin 3 and delta-
Myrtoxin-Mp1a); Myr p 3 is a disulfide linked homodimer of 8198 Da (also called Pilosulin 4); 
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and Pilosulin 5 is a disulfide linked homodimer of 8546 Da (175-179). All four peptides are 
highly basic and multiple isoforms of these peptides have been identified by genetic analysis 
or mass spectrometry (163). Myr p 2 is the only major allergen in M. pilosula venom and is 
identified by 78% of the population with M. pilosula venom allergy (174). The three 
dimensional structures of Myr p 1 and Myr p 2 have been determined by NMR spectroscopy 
(138, 178). A number of uncharacterized components of >20 kDa with IgE-binding capacity 
and <10kDa without IgE-binding capacity are known to be present in the M. pilosula venom 
(174). 
Table 2.   Lethal dose of various stinging ant venoms in animals 
Species LD50 (mg/kg)
a  Reference 
Myrmecia spp.     
M. pilosula 5.7 (23) 
M. pyriformis 2 ‒ 10 (166) 
M. nigriceps 7.3 (18) 
Pachycondyla spp.   
P. senaarensis 420.7 (180) 
P. goeldii 160 (180) 
Pogonomyrmex spp.   
P. maricopa  0.15 (18) 
P. badius 0.42 (78) 
P. rugosus 0.47 (74) 
P. barbatus 1.29 (9) 
Dinoponera spp. 
 D. gigantea 38 (181) 
Apis spp.   
A. mellifera 3.5 (23) 
aVenoms were administered to mice except for P. barbatus where it was administered to dogs, and to crickets for 
Pachycondyla spp.  
 
The cross-reactivity potentials of Mymercia ant venoms have been studied. Using 32 
sera from subjects allergic to the stings of Myrmecia ants and venom extracts from six 
Myrmecia ants species (M. pilosula, M. pyriformis, M. gulosa, M. nigrocincta, M. tarsata, 
and M. similima), it was shown that some degree of cross-reactivity exists between the 
different Myrmecia ant venoms analysed (182). Another study using sera from patients with 
IFA venom and Myrmecia venom allergies, showed that IFA and Myrmecia venoms have a 
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very low degree of cross-reactivity (161). Except for the Pilosulin peptides, IgE-binding 
components in other Myrmecia ant venoms have not been characterized thus far. 
 
3.3. Pachycondyla spp. 
Preliminary evidence indicated that the venom of P. chinensis likely contains 
hyaluronidase, phospholipase A2, histamine, formic acid and terpenes (121). One-
dimensional polyacrylamide gel electrophoresis (PAGE) analysis of P. chinensis venom 
extract showed the presence of at least 10 protein bands ranging from <14 to 90 kDa, with 
an intense band at approximately 29 kDa (57, 183). Immunoblot analysis showed the 
presence of two IgE-binding bands with an apparent molecular weight of 27 and 29 kDa 
(57). The presence of these IgE-binding bands was confirmed in a separate study, which also 
identified six additional IgE-binding bands with apparent molecular weights of 12, 22, 25, 31, 
46, and 58 kDa (56). Results from ELISA inhibition studies failed to detect cross-reactivity 
between P. chinensis and IFA venom, but demonstrated some cross-reactivity with yellow 
jacket venom and a very high degree of cross-reactivity with P. solitaria venom (56, 57, 122). 
Analysis of P. sennaarensis venom showed the occurrence of a volatile compound 
phenol-2,4-bis(1,1 dimethylethyl), a few terpenes including an alarm pheromone trimethyl 
pyrazine, and a small amount of unidentified peptides (55, 69, 180). Comparative 
toxicological analysis of 12 Pachycondyla spp. ant venoms, which include P. sennaarensis, 
confirmed their paralysing and lethal effects on animal prey (180). The LD50 of Pachycondyla 
spp. venoms are, however, much higher compared to the other medically important stinging 
ant venoms (Table 2). 
An immunoblot study of P. sennaarensis venom identified five IgE-binding proteins, two 
of which had an apparent molecular weight of 16 and 24 kDa (68, 127). A cross-reactivity 
study using immunoblot and sera from patients sensitized to P. sennaarensis venom showed 
some cross-reactivity with IFA venom. All sera tested bound to the 24 kDa allergen Sol i 3 
and some of the sera also bound the 13 kDa allergen Sol i 4 (127, 140). Further 
characterization of the 24 kDa IgE-binding band in P. sennaarensis venom was completed 
using P. chinensis venom, which resulted in the identification of a 23 kDa allergen named 
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Pac c 3 (183). Pac c 3 is a member of the antigen 5 family of proteins and has 54% homology 
to Sol i 3. Pac c 3 was added to the official list of Hymenoptera venom allergens in 2017 
(184). 
The venom of the arboreal ant P. goeldii contains 15 novel peptides with antibacterial, 
insecticidal and haemolytic properties that are collectively named Ponericins (185). When 
subjected to two-dimensional PAGE analysis, approximately 45 protein spots with a 
molecular weight of 10 to 66 kDa and pI between 4 and 10 were observed (62). Immunoblot 
of the resolved proteins using a serum sample from an allergic patient revealed four IgE-
binding protein spots of between 30 and 45 kDa (62). 
 
3.4. Pogonomyrmex spp. 
The venom of the harvester ant P. badius is primarily an aqueous solution with proteins 
constituting 73% of dry venom (27, 72). Separation of the venom using one-dimensional 
PAGE revealed the presence of at least nine protein bands (186). In one comparative study, 
the venoms of P. maricopa and P. rugosus were found to contain some basic proteins and a 
pair of highly expressed glycoproteins with a molecular weight of approximately 40 kDa 
(187). A biochemical study on P. badius venom showed that it contains exceptionally high 
phospholipase A2, hyaluronidase, acid phosphatase and lipase activity, and also has 
phospholipase B, alkaline phosphatases and several esterases (18, 79, 188, 189). Histamine 
and free amino acids were also found in the venom of P. badius, while kinin-like activity and 
kinin agonists were detected in the venom of P. maricopa (9, 188, 189). 
Physiological studies indicated that the venoms of P. badius and P. barbatus exhibit 
strong central and peripheral neurotoxicity in mammals (78, 186). Comparative toxicological 
analysis in mice showed that the venom of Pogonomyrmex spp. appears to be the most 
toxic Hymenoptera venom (Table 2), and is comparable to that of cobra venom (9, 76). In 
comparison to other stinging ant species, the venom of P. badius is highly haemolytic. Only 
4‒8 μg/mL venom induced more than 95% haemolysis in a 5% suspension of mouse 
erythrocytes (78, 79, 181). A further study on the haemolytic components in P. barbatus 
venom described the isolation of a highly basic, 34 amino acid polypeptide, with a pI of 10.0 
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and a molecular weight of 3.5 kDa, which was termed Barbatolysin (190). Another 
polypeptide with very high toxicity in mice and a pI of 8.0 and a molecular weight of about 8 
kDa was also reported in this study (190). 
Overall, P. maricopa and P. rugosus venoms exhibit similar immuno-profiles (187), which is 
consistent with immunological studies of patients sensitized to P. maricopa and P. rugosus 
that demonstrate antigenic cross-reactivity to the venom of seven other harvester ant 
species (73, 191). Thus, an individual sensitized to one species of Pogonomyrmex is likely to 
react to a sting from another species. Cross-reactivity studies of Pogonomyrmex whole-body 
extract (WBE) by immunodiffusion with commercial WBE of IFA, Camponotus spp. 
(carpenter ant), Formica spp. (wood ant), and a stinging insect mixture of honeybee and 
vespids did not observe any cross-reactivity potential (73). The venom allergens in 
Pogonomyrmex spp. have not been characterized thus far (76, 140, 154). The currently 




Table 3.   Allergen components of stinging ant venoms 
Species 




Glycosylated Properties References 
Fire ant (Solenopsis invicta) 
 
Sol i 1 37 + Member of phospholipase A1 protein (155, 156) 
 




Sol i 3 24 - Member of antigen 5 protein family (27, 153) 
 
Sol i 4 13.3 - Member of Sol i 2 family (100, 159) 
Jack Jumper ant (Myrmecia pilosula) 
 
Myr p 1 6.1 - Monomer peptide (174, 176) 
 
Myr p 2 5.6 - Heterodimer peptide  (174, 176) 
 
Myr p 3 8.2 - Homodimer peptide (174, 177) 
Asian needle ant (Pachycondyla chinensis) 
 
Pac c 3 23 - Member of antigen 5 protein family (183, 184) 
IUIS: International Union of Immunological Sciences
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4. Diagnosis of ant venom allergy 
The symptoms of anaphylaxis following an ant sting are comparable to anaphylaxis 
caused by other stinging Hymenoptera species. The interval between an Hymenoptera sting 
and symptoms typically occurs within half an hour (100). Symptoms of acute allergic 
reactions to Hymenoptera sting can manifest in the skin as itching, flushing, urticaria or 
angioedema; in the gastrointestinal tract as abdominal cramps, nausea, vomiting and 
diarrhoea; in the respiratory tract as dyspnoea, hoarseness, asthma or pulmonary oedema; 
and in the cardiovascular system as dizziness, hypotension, arrhythmia, collapse and loss of 
consciousness (153). These acute symptoms usually disappear within several hours, but 
delayed or biphasic anaphylactic reactions to Hymenoptera stings have also been reported 
(192, 193). Lasting morbidity such as myocardial or cerebrovascular infarction following 
severe reactions as well as fatalities may occasionally occur (4, 6, 194). 
Patients with anaphylaxis to the venom of stinging ants or other stinging Hymenoptera 
should be referred to an allergist. Evaluation of patients presenting with a potential 
Hymenoptera sting allergy must include a detailed clinical history (19, 195). Effort should be 
made to identify the offending insect species, but this may present considerable challenges 
(196, 197). Other useful clinical clues to the diagnosis of Hymenoptera sting allergy may 
include the description of a typical nest in the vicinity of the sting incident and the 
development of typical symptoms, e.g. sterile pustules with IFA sting, presence of jumping 
ants in sandy soiled area with M. pilosula sting, piloerection and sweating around the sting 
site with Pogonomyrmex spp. sting, etc. Diagnostic testing should only be performed if there 
is a definitive clinical history of systemic allergic reaction following a Hymenoptera sting 
(198). The diagnosis of Hymenoptera allergy is determined by correlation of the clinical 
manifestation of sting reactions with allergen-specific IgE as determined by intradermal 







4.1. Diagnostic tools 
4.1.1. Skin testing 
Skin testing is one of the 2 primary confirmatory tests for the presence of allergen-
specific IgE antibodies that are commonly used for the diagnosis of allergic disease (200), 
and is the gold standard for the diagnosis of Hymenoptera venom allergy (201). A skin prick 
or intradermal injection can be used to apply a Hymenoptera venom extract to the skin. 
However, skin prick testing with Hymenoptera venom is much less sensitive than 
intradermal injection and is often omitted in favour of intradermal test (195, 202, 203). The 
test concentrations which provide optimal sensitivity and specificity typically range between 
0.001 and 1 μg/mL for the diagnosis of Hymenoptera venom allergy by intradermal testing 
(202). Venom concentrations higher than 1 μg/mL may give improved sensitivity, but can 
also cause false-positive results because of local irritative effects (204). If however, higher 
concentrations of venom extract (e.g. 10 μg/mL) are required to achieve a greater 
diagnostic accuracy, dialyzed venom extract, which has naturally occurring histamine 
removed, can be used to reduce these irritative effects (200, 205). Skin testing should be 
performed at least 6 weeks after the sting reaction to avoid possible false-negative results 
during the refractory period, in which allergen-specific IgE antibody can be exhausted (201). 
Skin testing for venom allergy to IFA uses whole body extract (WBE), which is prepared 
by homogenising whole insect bodies (206, 207); although venom extract obtained from 
homogenates of dissected venom apparatuses might be superior (22, 208), it is not 
commercially available (see section 5 for further discussion on venom extract). Commercial 
preparations of S. invicta and S. richteri WBE for skin testing are available from Stallergenes-
Greer (Lenoir, NC, USA) and Hollister-Stier Laboratories (Spokane, WA, USA) (24, 68). 
Purified extract of M. pilosula venom, prepared by the Tasmanian Jack Jumper Allergy 
Program at the Royal Hobart Hospital is available (209, 210), and has been used in 
intradermal and in vitro testing for the diagnosis of M. pilosula venom allergy (211-213). 
WBE of P. sennaarensis for skin testing, prepared by Allerbio Laboratory (Varennes en 
Argonne, France), has been developed for the diagnosis of allergy to P. sennaarensis venom 
(68). Both WBE formulated in glycerine and venom extracts of P. chinensis have been used 
in skin testing and in P. chinensis venom allergy research (56, 57, 122, 183). P. rugosus WBE 
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preparations were available from Greer Laboratories, Hollister-Stier Laboratories and 
Meridian Biomedical Inc. (73). 
 
4.1.2. Serological testing 
 Serological (in vitro) based tests are an alternative diagnostic method commonly 
employed by physicians when skin testing is not possible, e.g. in patients with severe 
dermatographism, when patients are unable to discontinue medications with anti-
histaminergic activity, etc., or when the skin test is not safe to conduct, e.g. during 
pregnancy (214). Currently available in vitro test methods for the diagnosis of Hymenoptera 
venom allergy are primarily based on allergosorbent assays for the detection of allergen-
specific IgE antibodies. The accuracy of these assays may be affected by the activity of the 
many allergens in each venom, but also by their binding characteristics for the solid phase 
used in the assay (200, 215). 
 The radioallergosorbent test (Phadebas RAST, Phadia, Uppsala, Sweden) was the first in 
vitro assay developed for the detection of allergen-specific IgE antibodies (216). Its original 
method used allergen coupled to a cyanogen bromide-activated paper disc (allergosorbent) 
to bind allergen-specific antibodies of all isotypes from serum. After a buffer wash to 
remove unbound serum proteins, bound allergen-specific IgE antibodies were detected with 
a radiolabelled anti-human IgE (217). With technological advancements, the RAST assay has 
evolved into autoanalyzer-based assays, such as the ImmunoCAP system by Phadia, etc., 
that mimics the RAST’s solid phase chemistry (200). However, unlike RAST these assays do 
not use radiolabelled anti-human IgE and are calibrated by means of interpolation of 
response data from a heterologous serum IgE calibration curve that has been referenced to 
the World Health Organization IgE serum standard 75/502 (200, 218). The most significant 
advancement of these next-generation assays however, was the development of an 
encapsulated cellulose-based carrier polymer to which the allergen of interest was 
covalently coupled (218, 219). This polymer was three-dimensionally configured into the 
shape of a small cup and called a CAP. Its use in the Phadia ImmunoCAP system improved 
the allergosorbent’s overall IgE-binding capacity, which led to more rapid assay kinetics and 
enhanced assay sensitivity (217, 220-222). The Phadia ImmunoCAP system is commercially 
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available for detecting allergen-specific IgE to S. invicta WBE (223, 224), and to M. pilosula 
venom (225, 226). In addition to the ImmunoCAP system, an enzyme-linked immunosorbent 
assay (ELISA) or comparable in vitro assay for measurement of allergen-specific IgE has been 
developed for S. invicta (227), M. pilosula (225), and P. chinensis venom (57). No in vitro-
based assay is currently available commercially for the diagnosis of Pogonomyrmex spp. 
venom allergy. 
 
4.1.3. Sting challenge test 
A deliberate sting challenge using live insects may be considered as a reference method 
to confirm Hymenoptera venom allergy (228, 229). In this method, the offending insect 
species is allowed to intentionally inject its venom into the patient’s skin under medical 
supervision (198, 230). However, the sting challenge test is generally not recommended for 
routine use in the diagnostic workup of a suspected Hymenoptera venom allergy, due to the 
risk that deliberate stings could boost the already diminished sensitization, cause severe 
systemic/life threatening allergic reactions, or even re-sensitize the patients to the venom 
allergens (231). Instead, the sting challenge test is frequently employed in research 
environments where informed consent, placement of intravenous lines (cannula) pre-
challenge and appropriate medical personnel with experience in treating anaphylactic 
reactions are available (198). In this setting, the sting challenge test is typically used for 
assessing the effectiveness of Venom Immunotherapy (see following section) and to identify 
those who are not yet desensitised by the treatment under study. The sting challenge test 
with live ants has been used to confirm P. chinensis venom as the cause of anaphylaxis (124, 
232), and to assess the protection offered by Venom Immunotherapy against M. pilosula 
venom allergy (212, 213). 
 
5. Management of anaphylactic reactions to ant venoms 
The treatment of ant venom anaphylaxis is similar to the treatment of Hymenoptera 
venom anaphylaxis or other causes of anaphylaxis, and depends on the manifestations of 
the reaction. However, the rapid onset of venom-induced anaphylactic reactions requires an 
25 
 
aggressive treatment that must be started early. The acute management of anaphylaxis 
comprises the prompt use of epinephrine (adrenaline) injection, and potentially, 
intravenous fluids and/or supplemental oxygen in the presence of hypotension and 
respiratory symptoms, respectively (233). Cold compresses, antihistamines and analgesics 
may be used to treat swelling, pruritus, and local pain as required (233). In patients with a 
high risk of severe anaphylactic reactions from future Hymenoptera stings, a long-term 
management using a disease-modifying approach called Venom Immunotherapy (VIT) is 
indicated (193, 229, 234). VIT involves subcutaneous administration of increasing amounts 
of Hymenoptera venom extract (usually beginning with a dose of 0.001 to 1 μg and 
gradually increasing during initiation phase to a maintenance dose of 100 μg) for a period of 
3 to 5 years to induce and maintain long-term immunological tolerance to the offending 
venom allergens (229, 235). The following sections will focus on various aspects pertinent to 
stinging ant VIT. 
 
5.1. Mechanisms of Hymenoptera venom allergy and Venom Immunotherapy 
The allergic response to Hymenoptera venom is initiated by an exposure of antigen 
presenting cell cells (APCs) in the skin, including Langerhans cells in the epidermis and 
dendritic cells (DCs) in the dermis, to venom allergens after an incident involving 
Hymenoptera sting(s). Under the influence of the cytokine IL-4, APCs present venom 
allergens to polarise naïve CD4+ T helper (Th) cells to differentiate to the pro-allergic CD4+ 
phenotype, T helper type 2 (Th2) cells (236). Interleukin 4 and IL-13 cytokines produced by 
the activated Th2 cells cause B cells to class switch antibody production to generate 
allergen-specific IgE (sIgE). This sIgE binds to high-affinity FcεR1 IgE receptors on the surface 
of inflammatory effector cells (mast cells and basophils) and DCs, as well as to low-affinity 
FcεR2 IgE receptors on the surface of B cells thus ‘priming’ these cells (237, 238). Upon 
subsequent sting exposure(s), venom allergen(s) cross-link receptor-bound sIgE on mast 
cells and basophils, leading to cell degranulation and the release of inflammatory allergy 
mediators (histamine, leukotrienes, prostaglandins, etc.) and inflammatory cell enzymes 
(e.g. mast cell tryptase). Additionally, sIgE forms allergen-IgE complexes that more 
effectively bind to the IgE receptors on the surfaces of DCs and B cells. This further increases 
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the processing and presentation of venom allergen to naïve Th cells, resulting in enhanced 
Th2 cell activation and secretion of Th2 cytokines. Eosinophilic activation, maturation, 
survival and infiltration into tissues occurs in the presence of Th2 cell derived IL-4, IL-5 and 
IL-13 (236, 237). 
VIT works through complex immunological mechanisms, which are not completely 
understood, but appears to affect the fine balance between allergen-specific regulatory T 
(Treg) cells and Th2 cells, Th1 cells, or both. VIT is thought to induce immunological 
tolerance by the generation of allergen-specific Treg cells characterized by production of IL-
10 and/or TGF-β. These cytokines modify the response of Th2 cells to directly or indirectly 
influence effector cells of allergic inflammation (mast cells, basophils and eosinophils) and B 
cells, suppress sIgE production and induce the production of ‘blocking’ IgG4 and IgA 
antibodies against venom allergens (236, 239, 240). These immunological changes are 
summarized in Figure 3. 
 
Figure 3.   Proposed immunological mechanisms involved in Venom Immunotherapy 
Symbols in red indicate immunological changes and CD4+ shift which occur as a result of Venom 
Immunotherapy. APC: Antigen presenting cell; IFN-γ: Interferon gamma, Ig: Immunoglobulin; IL: Interleukin; 
TGF-β: Transforming growth factor beta; Th: CD4+ T-helper cell; Treg: Regulatory T cell; VIT: Venom 
Immunotherapy. Illustrations remain copyright of: www.ebi.ac.uk (allergen); www.123rf.com (antibodies); 
www.kisspng.com (APC); www.blausen.com (leukocytes). 
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5.2. Venom collection and purification 
Current diagnostic tests for Hymenoptera venom allergy and the preparations used in 
VIT are based on extracts of the allergen source materials. Consequently, a fundamental 
prerequisite is the development of appropriate methods to collect venom extracts. Stinging 
ants on average possess 10 μg of dried venom per individual with the largest ants (e.g. 
Myrmecia forficata) yielding up to 300 μg and the smallest (e.g. IFA) as low as 10 ng of 
venom proteins (149, 186). In comparison, spiders, scorpions, and snakes typically yield 
between 1 and 100 mg of venom per species (186). As stinging ants must typically be 
collected from the their nests in the field, obtaining ant venoms in reasonable quantities 
and purities may result in practical difficulties (18, 241). A number of methods for 
Hymenoptera venom collection have been described (207), but the two main methods of 
collecting venoms from stinging ants are by manual dissection of their venom sac and by 
electrostimulation (242). 
The venom sac dissection (VSD) technique was first introduced in 1964 and has been 
used for a variety of different arthropods (243). The method of venom collection by VSD 
begins with the collection of live insects from their nests, before the insects are snap-frozen 
at ‒20oC or lower. The frozen insects are then thawed for species identification, quality 
controlled for parasites, dirt and other contaminants, before the venom sac is removed. The 
collected venom sacs are lightly crushed, homogenized and filtered to purify the venom 
(244-246). This basic VSD technique was developed further for commercial purposes by 
scientists at Vespa Laboratories together with scientists at the Hollister-Stier Laboratories 
(247). The VSD procedure requires good hand-eye coordination and patience as the venom 
sacs are extremely fragile and any rupture during dissection will lead to venom loss (248). 
The obvious disadvantage of VSD is that the ants must be sacrificed. This method has been 
employed to extract venoms from Myrmecia (41, 42, 168, 182, 211), Pachycondyla (55, 57, 
62), and Pogonomyrmex ants (78, 79, 188, 190). 
The electrostimulation method was first described by Markovic and Molnar in 1954 for 
obtaining venom from honeybees (Apis mellifera) (202) and was perfected by Benton et al. 
in 1963 (249). The procedure is relatively simple and was adapted to collect venom from 
other Hymenoptera insects, including vespid and stinging ants (73, 242, 250). The potential 
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advantages of electrostimulation are that it may give a higher yield of venom if performed 
en masse, is less time consuming and keeps the insect alive for subsequent venom 
extraction (249). In practice however, electrostimulation is not particularly effective for 
collecting venom from ants because unlike honeybees, they do not readily release their 
venom when stimulated (18), however it has been used to collect venoms from IFA (151), 
M. pilosula (176, 210), M. gulosa (171), and Pogonomyrmex ants (18). 
An alternative method of venom collection is to ‘milk’ the venom from individual live 
ants into glass rods, capillary tubes, or through membranes (154, 245). The venom is then 
collected by washing it with an appropriate buffer (248). Small to moderate amounts of 
relatively pure venom can be collected, but the method is tedious and inefficient for 
commercial use (244). For safety, it is recommended that ants be chilled and pinned, and 
handled with the pins while the ants are being ’milked‘ (154). 
After extraction from the source material, the resulting venom extract is clarified to 
separate solid contaminants from aqueous extract. Typically, a series of graded filters is 
used for clarification, but other techniques such as dialysis and centrifugation, may also be 
used. Venom extract is then filtered through a 0.2 μm filter for sterilization and is usually 
freeze-dried and stored frozen (244). 
Problems do exist in the methods of venom collection and venoms may contain small 
amounts of non-venom proteins (251). The main contaminants of venom obtained using 
electrostimulation are stinger lancets, mouth secretions, faecal material and body hairs (18, 
154). Studies by others suggest that dissected venom extracts contain most of the proteins 
that are in electrically stimulated venom, but also other proteins that are usually 
contaminants from the venom sac, including structural and cellular proteins (242, 252). 
While venom produced by electrical stimulation may give a more genuine representation of 
the venom components, the method may not be suitable for collecting venom from 
aggressive Hymenoptera species such as Myrmecia ants and vespids (241, 253). Venom 
collection by this method can be dangerous as the electrically stimulated species will release 
alarm pheromone and volatile sting substances, causing relevant species in the area to react 
simultaneously and resulting in uninvolved persons being attacked and stung (154, 253). 
Although both the electrostimulation and VSD methods have been used in the past to 
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obtain venom extract from M. pilosula (176, 210), venom from this highly aggressive ant 
species is best collected using the VSD method largely for the reasons described above. 
The venom sac of each IFA contains about 40 nanolitre of venom (145). This minute 
amount of venom can be laboriously collected by either having live ants directly stinging 
into capillary tubes or by hand-milking venom from dissected venom sacs into micro-
capillary pipettes under a dissecting microscope (22, 151). Both methods are extremely 
laborious and the amount of venom obtained is small. More recently, an alternative method 
for the extraction of IFA venom has been described, which involves soaking large quantities 
of fire ants in a dual-phase mixture of non-polar organic solvent and water (254). However, 
solvent extractions are bound to select for classes of compounds based on their relative 
solubility and may result in venom losses during the evaporation step (255). A proprietary 
modified electrical stimulation technique was developed by Vespa Laboratories for the 
collection of a prototype commercial-grade IFA venom (151, 154); the currently available 
commercial products are however, still prepared from whole body extracts (202). 
 
5.3. Standardization and stability of ant venom extracts for human use 
Comparable to other venomous animals, the synthesis and chemical composition of 
venoms from various stinging ants vary with time and are influenced by endogenous and 
exogenous factors (256-261). Likewise, seasonal variation in allergenic composition and 
activity has also been shown for venom extracts of the IFA, S. invicta (262). Accordingly, 
allergenic composition in different batches of venom extracts is expected to vary and the 
use of non-standardized venom extracts in the diagnosis of Hymenoptera venom allergy 
and/or VIT is likely to lead to variations in treatment outcomes. To minimize this potential 
variability, venom extracts must be prepared and standardized according to regulatory 
requirements for the manufacture of allergen products (263-266). Although the 
standardization of allergen products varies for each allergen extract, the process generally 
consists of the following steps: (i) characterizing prospective reference allergen extract 
preparations, (ii) identifying major and minor allergenic components in allergen extract, (iii) 
measuring biological potency of reference allergen extract in human subjects, (iv) 
developing and validating in vitro assays to predict biological potency using reference 
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allergen extract as the standard, (v) obtaining manufacturing licenses for commercial 
distribution, and (vi) establishing a Quality System to monitor the regulatory compliance for 
each manufactured allergen product (215). 
 The concept of allergen extract standardization, which is one of the cornerstones of 
allergen immunotherapy, was first introduced by Noon in the early 1900s (267). Allergen 
extracts are highly heterogeneous mixtures containing multiple allergenic components as 
active ingredients as well as non-allergenic components (268). Thus, owing to their complex 
nature, the standardization of allergen extracts is challenging. The modern concept of 
allergen extract standardization became a reality in the 1970s when the U.S. Food and Drugs 
Administration (FDA) released the criteria of allergenic potency and allergen composition 
(269). Central to allergen extract standardization is the use of reference standards (270). 
Manufacturers of “standardized” allergen products for commercial distribution in the USA 
must use US reference standards and serum pools specified by the FDA Centre for Biologics 
Evaluation and Research (CBER) when conducting potency test (263, 266). These 
standardized products are released and labelled in common bioequivalent allergy units 
(BAUs) (269), or in micrograms of protein for Hymenoptera venoms (161). In the absence of 
a US reference standard, the product is exempted by regulation from potency testing and 
stability study, and is labelled as a “non-standardized” allergen product (263). On the 
contrary, those manufacturers of allergen products that follow the quality requirements 
specified in the European Pharmacopoeia monograph on Allergen Products must prepare 
their own in-house reference (IHR) standard and create their own allergen extract units 
accordingly (271-273). 
 Allergen extract batches manufactured for commercial use must be compared with the 
reference standard using validated qualitative and quantitative in vitro assays before batch 
release (244). Established in vitro assay methods for allergen standardization must be able 
to measure allergenic potency and activity, ensure purity and consistency in allergen 
composition, and demonstrate the stability of relevant allergens in the extracts (265, 274). 
Storage conditions, particularly temperature and allergen extract dilution, can affect 
product quality and potency (275-278). Endogenous proteases, frequently present in 
allergen extracts, can also lead to the degradation of some allergens during storage (279-
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281). Thus, stability studies must be performed to enable proper expiration dating of 
allergen products (202, 282). 
 Initial estimations of allergenic extract potency are made by measuring total protein 
content in the extract using the FDA-approved Lowry (202), or Bradford, ninhydrin, or 
bicinchoninic acid methods (246, 268). During the commercial development of 
Hymenoptera venom extracts in the late 1970s, the enzymes phospholipase and 
hyaluronidase were discovered to be major allergenic proteins in Hymenoptera venoms 
(202). Functional assays for enzymatic activity confirmed the presence of these enzymes in 
Hymenoptera venoms and these assays became part of the Hymenoptera venom extract 
potency testing (202, 266, 283, 284). 
 The discovery of IgE antibodies by Ishizaka et al. in 1966 (285), and the development of 
immunoassays that measure allergen-specific IgE, led to the use of RAST inhibition and later, 
ELISA inhibition assay, in potency testing of allergen extracts (266, 286). These assays rely on 
high-affinity binding interactions between allergens and IgE antibodies derived from human 
allergic sera (268). The immunoassay approach is, however, highly dependent on the ability 
of the allergen-specific IgE antibodies to bind the allergens, and variability of the specificity 
and concentration of the allergen-specific IgE in serum from the selected patients (215, 
287). The identification, purification and characterization of relevant allergenic components 
from various allergen sources have allowed the direct quantification of specific allergen 
content in allergen extracts (215). Assay methods that are based on monoclonal and 
polyclonal antibodies that recognize specific allergens, such as the sandwich ELISA assay, 
have been employed for the standardization of allergen extracts (268, 288). Unlike the RAST 
and ELISA inhibition assays, this approach is not dependent upon variation in the specificity 
of patients’ allergen-specific IgE antibodies (215). 
 When specific allergen content cannot be quantified, qualitative assay methods can be 
employed to monitor the identity, consistency and purity of allergen extracts (215). 
Additionally, qualitative assays can also serve to complement quantitative analyses (268). In 
these methods, banding patterns and allergen profiles of allergen extract components, 
usually produced after electrophoretic separations in porous gels based on molecular 
weight, charge, or pH differences, are compared to reference standards to establish the 
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identity and protein composition in the allergen extract batches. Electrophoresis techniques 
such as isoelectric focusing (IEF), polyacrylamide gel electrophoresis (PAGE), and crossed 
immunoelectrophoresis (CIE) have been employed to confirm the identity, consistency and 
purity of allergen extracts (268, 289). Allergen profiles in extracts can be assessed using 
techniques such as PAGE coupled with immunoblotting, crossed radio-
immunoelectrophoresis, or mass spectrometry (287, 290). 
 Presently, there are two stinging ant-derived products available to diagnose and treat 
ant venom allergy. The IFA WBE are “non-standardized” commercial products available in 
the USA, which are neither standardized for potency nor for the presence of the Sol i 
allergens (161). The concentration of these products is labelled as 1:10 weight/volume of 
whole-body extracts (244), but an evaluation of three IFA WBE commercial products by 
crossed immunoelectrophoresis and RAST inhibition assays showed major differences in 
their antigen contents (291). Furthermore, batch-to-batch variability and stability of these 
products are not known (202). Purified M. pilosula venom (Jack Jumper Ant Venom; JJAV) 
extract is available in Australia (292). This product, in contrast, is standardized and labelled 
with concentration of venom protein in mg/mL (210, 293). The standardization procedure, 
consisting of five complementary assays (Table 4), satisfies the requirements described in 
the European Pharmacopoeia monograph for Allergen Products (272). While information on 
batch-to-batch variability of this product is not available, the stability of JJAV extract and 
diluted preparations containing as low as 0.1 μg/mL of venom protein has been studied 
(293). 
 
5.4. Efficacy and adverse events associated with stinging ant VIT 
The high efficacy of VIT to prevent future sting anaphylaxis caused by social 
Hymenoptera was shown in multiple systematic reviews and meta-analyses (294-297). To 
date however, there is only one randomised double-blinded, placebo-controlled trial of VIT 
against stinging ant allergy, with a deliberate sting challenge test used as a measure of 
treatment efficacy (153, 292). This trial showed that treatment with M. pilosula (Jack 
Jumper ant; JJA) VIT is highly effective at preventing life-threatening anaphylaxis secondary 
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to a deliberate sting with live ants. An objective systemic sting reaction rate of less than 5% 
was observed in patients in the VIT arm compared to 72% in the placebo arm (211). 
 
Table 4.   Analytical methods employed in the standardization of JJAV extracts intended for 
venom allergy diagnosis and treatment 
Quality requirements Method Acceptance criteria References 
Quantitative assays 








50‒150% of IHR (210, 272) 
Relevant allergen 
content 
HPLC-UV 50‒200% of IHR (176, 210) 
Qualitative assays 
   
Protein profile SDS-PAGE 
Comparable protein 











As VIT involves injecting patients with a venom extract to which they have specific IgE-
mediated allergy, the most common side effects of VIT are systemic allergic reactions, which 
more often occur during the up-dosing phase of treatment (294, 298). Unlike reactions to 
wild stings, reactions to venom extract given during VIT are usually mild in nature (e.g. 
itching, swelling and erythema at injection site, urticaria) due to the gradual up-dosing/slow 
initiation phase. However, in rare instances reactions to VIT can be so severe (e.g. 
hypotensive reactions, anaphylaxis) that they require treatment with epinephrine and/or 
intravenous fluids (298, 299). Recurrent reactions can prolong the time required to achieve 
maintenance dose. Systemic reactions can also be uncomfortable and/or distressing to 
patients and when combined with the need for regular visits for treatment continuation, 
this can reduce patient compliance and premature discontinuation of treatment. For JJA VIT, 
the risk of adverse reactions is influenced by the rate of initiation and target maintenance 
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dose (212, 292). Higher rates of systemic reaction occur with fast initiation “ultra-rush” 
compared to slower initiation “semi-rush” with lower maintenance doses. 
 
5.5. Enhancing the safety and efficacy of VIT using an immunomodulatory adjuvant 
Finding new strategies to enhance the safety, efficacy and more compact treatment 
regimens represent major objectives of current research efforts to improve the delivery of 
VIT and other forms of Allergen Immunotherapy (AIT) (300). Many innovations and 
modifications of AIT have been reported (237, 301-303), among these, adjuvants have been 
shown as encouraging candidates to improve the efficacy and safety of AIT by modulating 
the non-allergic part of the immune system (Th1 cells) or tolerance-inducing immunological 
mechanisms (Treg cells) (304). Adjuvants, from the Latin word adjuvare, which means ‘to 
help’ or ‘to enhance’ (305), are all substances that have the potential to enhance the 
immunogenicity of antigens or allergens. However, adjuvants must themselves be 
pharmacologically inactive and develop an immunomodulatory effect only in combination 
with a specific antigen or allergen (304). The use of appropriate adjuvants that skew the 
immune response toward Th1 and/or Treg and down-regulate the pro-allergic Th2 cell 
phenotype is therefore a promising strategy to improve the safety and efficacy of AIT. 
Additionally, a stimulated immune system may require a lower allergen dose and thus 
reduce AIT-associated side effects by avoiding allergen-IgE complexes (300, 306). However, 
adjuvants can also cause adverse events, raising clinical concerns about their use (307). 
The ideal adjuvants should be cost effective, biodegradable, non-toxic, stable for 
extended periods of time in vivo and induce an appropriate immune response (308). 
Different adjuvants have been used and/or proposed to enhance the efficacy and safety of 
AIT and to simplify immunotherapy regimens (309, 310). To date, the most commonly used 
adjuvant in AIT is Alum, a mixture of aluminium hydroxide, phosphate and sulfate salts, 
which is used to increase the duration of antigen presentation (302, 311). Alum is however, 
a relatively weak adjuvant and mainly induces Th2 immunity while stimulating high and 
persistent levels of IgE antibodies, which limits its use in long-term therapies (300, 312). 
Additionally, the use of Alum in human vaccines has been linked to persistent intradermal 
granuloma formation, macrophagic myofasciitis and autoimmune/inflammatory syndrome 
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(311, 313). Recent advances in developing new forms of adjuvants for AIT have focused on 
the reduction of potential adverse events while modulating the immunogenicity of AIT 
(310). 
Carbohydrates have been recognized to play a critical role in stimulation and regulation 
of immune responses (311). A major advantage of the use of carbohydrates is their high 
biocompatibility and low toxicity in vivo (314). A wide variety of carbohydrate structures 
have been tested as adjuvants, with polysaccharides believed to be the most promising 
carbohydrate structures for vaccine development (314). One potential candidate is the delta 
inulin-based adjuvant, Advax™. Advax is based on the plant derived fructan inulin (β-D-
[2→1] poly(fructo-furanosyl) α-D-glucose; Figure 4) (314, 315). Inulin has no immunological 
activity when in soluble form, but once formulated into delta inulin microparticles of 1-10 
μm size, it shows potent immunomodulatory activity (311, 316-320). 
 
Figure 4.   Structure of an inulin polymer 
Inulin polymer comprises of a variable length chain of fructose units [n] terminated with a single 
glucose moiety. 
 
In preclinical studies, Advax enhanced the immunogenicity of a broad range of vaccines 
including influenza, hepatitis B virus (HBV), Japanese encephalitis, SARS coronavirus, HIV, 
listeria, RSV, and anthrax (321-323). Furthermore, the safety and efficacy of Advax has been 
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shown in adult humans when formulated with HBV and influenza vaccines (307, 321, 324). 
One possible mechanism of action of Advax has been proposed recently. It is thought that 
Advax may enhance antigen uptake and T- and B-cell responses to co-administered antigen 
by recruiting and priming APCs (325). A recent study using a combination of Advax with 
honeybee VIT administered to individuals with honeybee-sting anaphylaxis showed that 
Advax was safe, enhanced the immunogenicity of honeybee venom, and strongly enhanced 
allergen-specific IgG4 responses (326). Therefore it is likely that, in combination with 
stinging ant Venom Immunotherapy (e.g. JJA VIT), Advax may facilitate a desirable immune 
response to the venom allergen, allowing a reduction in allergen dose, reduced frequency of 
adverse effects and reduced treatment cost by reducing venom requirements. 
 
5.6. Overview on the development of Jack Jumper ant Venom Immunotherapy 
 Developments in the field of M. pilosula (Jack Jumper) ant Venom Immunotherapy 
began in 1964 when allergy to M. pilosula ant stings was scientifically described for the first 
time by Dr John Trinca (117). Around the same time, immunotherapy with M. pilosula whole 
body extracts, prepared at the former Commonwealth Serum Laboratories (now CSL 
Limited), was made available on the Australian Government Pharmaceutical Benefit Scheme 
and provided to scores of patients from the 1960s onwards (14, 327). It was Dr Struan 
Sutherland of CSL ‒ the Doyen of envenomation in Australia (328), who first commented in 
1980 that pure ant venom preparations would be preferable to whole body extracts for 
immunotherapy purposes (329). His suggestion stemmed from a personal observation of 
the failure of whole body extract immunotherapy in protecting anaphylactic reaction during 
sting challenge and a published case study by Lichtenstein et al. of successful 
immunotherapy with honeybee venom extract (330, 331). This was supported by further 
research by the same group, in which a double-blind, placebo-controlled trial with vespid 
venom extract demonstrated the efficacy of Venom Immunotherapy in preventing systemic 
reactions to insect sting challenge. This study also showed that the preventative activity of 
whole body extracts was comparable to placebo (332). Despite best efforts, Dr Sutherland 
reported in 1983 that the proposals to prepare immunotherapy from the venom gland 
extracts of M. pilosula had to be shelved due to the lack of funding (327). 
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The natural history and the extent of the problem with M. pilosula stings was first 
described by a Tasmanian allergist Dr Paul Clarke in 1986, who conducted a survey on this 
issue in the Tasmanian population (48). In his report, Dr Clarke also remarked on the 
unavailability of controlled clinical trial data to assess the prophylactic value of M. pilosula 
whole body extracts, the absence of biochemical and pharmacological analysis on M. 
pilosula venom, and the value of immunotherapy with pure Hymenoptera venom. In his 
attempts to answer these concerns, Dr Struan Sutherland studied patients’ response to 
immunotherapy with whole body extract preparations produced by CSL over a three-year 
period. In this research, immunotherapy with whole body extract from crushed ants was 
found to be ineffective (42, 333), and as a result of this finding the production of M. pilosula 
whole body extracts was ceased in the late 1980s (14, 333). Soon after the problem with M. 
pilosula whole body extract was recognised, Dr Sutherland was awarded an Australian 
Federal Government grant to collect venom of Myrmecia ants for desensitisation purposes 
(334). Large quantities of venom sac extracts, primarily intended for skin testing of patients, 
the testing of their sera and their immunotherapy, were accumulated at CSL between 1989 
to 1993 (42). The main aim of this initiative was to make Myrmecia ants Venom 
Immunotherapy available for treatment by 1994 (331). In conjunction with these works, 
detailed studies on M. pilosula venom were performed in the 1990s by two groups (328). 
Studies on pharmacological and biochemical properties of M. pilosula venom were 
conducted by a group at the Department of Pharmacology at Monash University in 
Melbourne in collaboration with Dr Sutherland. They found evidence for the presence of 
histamine, a heat-sensitive haemolytic factor, and eicosanoid-releasing factors (167), and 
detected phospholipase A2, phospholipase B, hyaluronidase, acid phosphatase, and alkaline 
phosphatase activities in M. pilosula venom (165). Another group, led by Dr Brian Baldo of 
the Kolling Institute of Medical Research at The Royal North Shore Hospital in Sydney and in 
collaboration with Dr Sutherland, aimed to characterise Myrmecia venoms and to develop 
Venom Immunotherapy against M. pilosula and M. pyriformis (328, 335). Dr John Weiner, an 
allergist from the Alfred Hospital in Melbourne, was to be in charge of the clinical trials of 
the Venom Immunotherapy preparations (331). In their initial work, three IgE-binding 
peptides were identified from the venom of M. pilosula (336). Further studies performed by 
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this research group successfully cloned, sequenced and characterized two IgE-binding 
peptides, which cDNA they named Myr p 1 and Myr p 2 (337-341). The expressed clones of 
Myr p 1 and Myr p 2 were found to account for most, but not all, of the venom-specific IgE 
antibody-binding peptides observed on SDS-PAGE immunoblots of native venom (42). The 
initiative to produce Myrmecia ant Venom Immunotherapy led by Dr Sutherland eventually 
failed because of technical problems to standardise venom extracts, under-funding and the 
privatisation of CSL in 1994 (42, 331). Despite the setback, research on the prevalence, 
natural history and fatalities from systemic allergic reactions to ant venoms in Australia 
continued to take place in the late 1990s (11, 13, 14, 50). Ultimately, the high incident of 
systemic allergic reactions and fatalities attributed to M. pilosula in Tasmania provided a 
new stimulus to develop Venom Immunotherapy against this stinging ant (11). 
The development of an effective Venom Immunotherapy for M. pilosula allergy in 
Tasmania was instigated by Dr Bryan Walpole and continued by Dr Simon Brown of the 
Royal Hobart Hospital Department of Emergency Medicine (342). The efficacy of M. pilosula 
Venom Immunotherapy was successfully demonstrated in 2003 in a double-blind, placebo-
controlled crossover trial led by Dr Brown (211). In this study, 72% of participants in the 
placebo arm produced objectively defined systemic reactions to in-hospital sting challenges 
compared to mild reaction in 3% of participants receiving Venom Immunotherapy. In spite 
of the success, significant reaction rates of around 34% were also observed during the 
course of immunotherapy with M. pilosula venom extract (211). Following this study, the 
allergenic components in M. pilosula venom were re-examined by the Tasmanian research 
team (176, 343). Major components in M. pilosula venom were characterised by mass 
spectrometry and it became clear that the original descriptions of the allergenic peptides 
bases on cDNA sequencing were not entirely correct. A subsequence of the Myr p 2 cDNA 
was found as a disulfide linked, antiparallel aligned heterodimer consisting of Myr p 2 49 → 
74 (des–Gly27-pilosulin 2) and a previously unreported peptide of 2457 Da, while Pilosulin 1, 
a subsequence of the Myr p 1 cDNA, was found to exist mainly as [Ile5]pilosulin 1 (176). 
Further analysis of M. pilosula venom described novel peptides Pilosulin 4.1 (Myr p 3) and 
Pilosulin 5 (175, 177), and identified thirteen IgE-binding bands in the venom (174). Pilosulin 
3 (Myr p 2) was found to be the only major allergen, whilst [Ile5]pilosulin 1 (Myr p 1) and 
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pilosulin 4.1 (Myr p 3) were found to be minor allergens (see Chapter 2 for detailed 
discussion on this topic). There are additional IgE-binding proteins in the venom that require 
further characterization (174), but the detailed analyses provided an adequate framework 
for developing a standardization procedure of M. pilosula venom extracts for Allergen 
Immunotherapy that complies with the requirements described in the European 
Pharmacopoeia (210, 343). The optimal formulation and stability of purified M. pilosula 
venom extracts for use in diagnosis and Venom Immunotherapy was determined (293), and 
the protocol for M. pilosula Venom Immunotherapy was further refined in another 
randomised controlled trial comparing different treatment regimens (212). 
The need for ongoing research to investigate the use of low-dose protocols, 
immunological adjuvants, and pharmaceutical research to investigate optimal conditions of 
M. pilosula Venom Immunotherapy for distribution and supply to clinicians was recognised 
by the Australian Society for Clinical Immunology and Allergy (209, 292), which inspired this 
PhD research. The results of my research and its implications for the delivery of M. pilosula 




Chapter 2: In-depth review of Jack Jumper ant venom components 
2.1. Introduction 
Due to their allergenic potential and impact on human health, studies on JJAV and other 
Myrmecia ant venoms have been performed by many research groups in the last few 
decades, which resulted in a wealth of available information on this subject. Unfortunately, 
some of the reported data was found to be conflicting and a source of confusion; for 
examples see (174, 176, 177). A detailed examination and review of published data was 
therefore required in order to clarify the correct properties of this highly allergenic venom. 
In this foundational work, I performed a comprehensive literature search for published 
information on Myrmecia ant venoms and critically evaluated the available data. I 
consolidated and cross-referenced our present knowledge on the structural characteristics 
and mode of action of various bioactive peptides contained within JJAV, and identified the 
knowledge gaps that require further studies. 
 
2.2. Published manuscript 
A manuscript describing this work has been published in Toxicon. An electronic reprint is 
provided. 
 
T. Wanandy, N. Gueven, N.W. Davies, S.G.A. Brown, M.D. Wiese. Pilosulins: A review of the 
structure and mode of action of venom peptides from an Australian ant Myrmecia pilosula. 




















Chapter 3: Study objective and research questions 
3.1. Study objective 
The objective of this thesis was to advance the quality, safety and efficacy of pharmaceutical 
grade venom extracts, prepared from the jumper ant Myrmecia pilosula, that are used in in 
vitro and in vivo diagnoses of allergen sensitization and in Venom Immunotherapy. I set a 
number of clinically relevant research questions as a framework for addressing my 
objective. 
 
3.2. Research questions and hypothesis 
Question 1: What are the intrinsic and extrinsic factors influencing batch-to-batch 
consistency of Jack Jumper ant venom as Pharmaceutical Grade products? 
Hypothesis: Poor knowledge of intrinsic and extrinsic determinants of batch-to-
batch consistency will negatively impact product quality. 
 
Question 2: Can I establish the identity of high molecular weight components with IgE-
binding properties in Jack Jumper ant venom? 
Hypothesis: Improved knowledge and understanding of venom allergens will aid 
treatment safety and efficacy, including determination of their cross-reactivity 
potentials, implementation of component-resolved diagnostics and personalized 
treatment. 
 
Question 3: Is there a relationship between IgE recognition to specific venom components 
and risks for developing side effects or therapeutic failure? 
Hypothesis: The safety and efficacy of Venom Immunotherapy is strongly 




Question 4: Can immune-modulatory adjuvant be incorporated in the formulation for Jack 
Jumper ant Venom Immunotherapy? 
Hypothesis: Adding appropriate immune-modulatory adjuvant to Venom 
Immunotherapy will improve the safety and efficacy of this treatment modality. 
 
Question 5: Can I establish a robust handling and storage requirements for Jack Jumper 
ant venom products so to ensure preservation of allergenic activities during clinical use? 
Hypothesis: A scientifically solid framework of handling and storage requirements 





Part II: RESULTS 
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Chapter 4: Production and quality of Jack Jumper ant venom as 
pharmaceutical grade products 
4.1. Introduction 
Since 2007, the Tasmanian Jack Jumper Allergy Program at the Royal Hobart Hospital 
(Australia) has produced purified allergen extracts from JJAV for use in ant venom allergy 
diagnosis and in VIT. The preparation of JJAV extracts as pharmaceutical grade products (in 
the form of Active Pharmaceutical Ingredient) is a licensable manufacturing activity, which 
must be performed under current Good Manufacturing Practice (cGMP) requirements. The 
products are standardised prior to batch release (210), but batch-to-batch consistency of 
the extracts is currently not known. Furthermore, detailed requirements for proper handling 
and storage conditions of the extracts were not fully understood. In this part of the PhD 
project, I examined the various intrinsic and extrinsic factors that could influence batch-to-
batch consistency and quality of JJAV extract as Active Pharmaceutical Ingredients. I also 
aimed to establish the handling and storage requirements of JJAV extracts to ensure 
preservation of allergenic activities during usage in in vitro and in vivo diagnoses of venom 
sensitization and in VIT. 
 
4.2. Published manuscript 
A manuscript describing this work has been published in Clinical and Experimental Allergy. 
An electronic reprint is provided. 
 
T. Wanandy, H.E. Dwyer, L. McLean, N.W. Davies, D. Nichols, N. Gueven, S.G.A. Brown, M.D. 
Wiese. Factors influencing the quality of Myrmecia pilosula (Jack Jumper) ant venom for use 
in in vitro and in vivo diagnoses of allergen sensitization and in allergen immunotherapy. 
Clinical and Experimental Allergy. 2017; 47:1478-1490. (DOI: 10.1111/cea.12987)  
This article has been removed for 
copyright or proprietary reasons.
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4.3. Supporting information 
 
  
Supplementary Figure 1.   A typical HPLC-UV chromatogram of JJAV IHR showing the 
quantified peaks and retention times corresponding to the allergenic peptides Myr p 1, Myr 





Supplementary Figure 2.   Batch-to-batch consistency of JJAV APIs as analysed using SDS-
PAGE with Imperial Protein stain (A) and SDS-PAGE Immunoblot (B) methodologies. Lanes: 
1. JJAV IHR, 2. API batch 2-02, 3. API batch 2-03, 4. API batch 3-01, 5. API batch 3-02, 6. API 




Supplementary Figure 3.   Effects of elevated temperature on the stability of JJAV analysed 
using SDS-PAGE with silver stain (A), SDS-PAGE Immunoblot (B), AU-PAGE with silver stain 
(C), and AU-PAGE Immunoblot (D) methodologies. JJAV APIs (1 mg/mL) were incubated at 
various temperatures for 2 hours. For figures (A) and (B) lanes: 1. MW standards, 2. Empty, 
3. Baseline sample, 4. Treatment sample incubated at 20oC, 5. Treatment sample incubated 
at 40oC, 6. Treatment sample incubated at 60oC, 7. Treatment sample incubated at 80oC. For 
figures (C) and (D) lanes: 1. JJAV IHR, 2. Baseline sample, 3. Treatment sample incubated at 
20oC, 4. Treatment sample incubated at 40oC, 5. Treatment sample incubated at 60oC, and 




Supplementary Figure 4.   Effects of vial inversion on JJAV analysed using SDS-PAGE with 
silver stain (A), SDS-PAGE Immunoblot (B), AU-PAGE with silver stain (C), and AU-PAGE 
Immunoblot (D) methodologies. JJAV APIs (1 mg/mL), protected from light and stored 
refrigerated at 4oC, were kept in inverted position to ensure full exposure to the inner 
surface of grey butyl rubber stoppers for various period of time. For figures (A) and (B), 
lanes: 1. MW standards, 2. Baseline sample, 3. Treatment sample incubated for 6 hours, 4. 
Treatment sample incubated for 24 hours, 5. Treatment sample incubated for 48 hours, 6. 
JJAV IHR. For figures (C) and (D), lanes: 1. JJAV IHR, 2. Baseline sample, 3. Treatment sample 
incubated for 6 hours, 4. Treatment sample incubated for 24 hours, and 5. Treatment 




Supplementary Figure 5. Effects of artificial light and storage temperatures on JJAV (1 
mg/mL) as analysed by SDS-PAGE with silver stain (A), SDS-PAGE Immunoblot (B), AU-PAGE 
with silver stain (C), and AU-PAGE Immunoblot methodologies. For figures (A) and (B), lanes: 
1. MW standards, 2. Baseline sample, 3. Treatment sample incubated at 4oC with no light for 
24 hours, 4. Treatment sample incubated at 4oC with artificial light for 24 hours, 5. 
Treatment sample incubated at 4oC with no light for 48 hours, 6. Treatment sample 
incubated at 4oC with artificial light for 48 hours, 7. Baseline sample, 8. Treatment sample 
incubated at 25oC with no light for 24 hours, 9. Treatment sample incubated at 25oC with 
artificial light for 24 hours, 10. Treatment sample incubated at 25oC with no light for 48 
hours, 11. Treatment sample incubated at 25oC with artificial light for 48 hours, and 12. JJAV 
IHR. For figures (C) and (D), lanes: 1. JJAV IHR, 2. Baseline sample, 3. Treatment sample 
incubated at 4oC with no light for 24 hours, 4. Treatment sample incubated at 4oC with 
artificial light for 24 hours, 5. Treatment sample incubated at 4oC with no light for 48 hours, 
6. Treatment sample incubated at 4oC with artificial light for 48 hours, 7. Baseline sample, 8. 
Treatment sample incubated at 25oC with no light for 24 hours, 9. Treatment sample 
incubated at 25oC with artificial light for 24 hours, 10. Treatment sample incubated at 25oC 
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with no light for 48 hours, and 11. Treatment sample incubated at 25oC with artificial light 




Chapter 5: Identification of Jack Jumper ant venom components with IgE-
binding capacity and their clinical relevance 
5.1. Introduction 
Around 80% of patients who are allergic to JJAV are known to recognise Myr p 2, and this 
major allergen comprises about 50% of JJAV protein (174, 176, 177). However, previous 
research revealed that many patients are either not susceptible to this allergen, or are also 
reacting to other allergens such as Myr p 1, Myr p 3, or to the higher molecular weight 
venom components (>20 kDa) with IgE-binding capacity (174). Importantly, these 
components are present in JJAV in much lower quantities (343). It is possible that individuals 
who are allergic to allergens other than the major allergen Myr p 2, and therefore receive 
much less of it in JJA VIT, are more likely to fail JJA VIT and/or are more or less likely to 
suffer side effects from JJA VIT. Notably, from the study described in the previous chapter, it 
became clear that exposure of JJAV to elevated temperature above 40oC degrades the 
higher molecular weight components of >20 kDa. This could potentially compromise the 
quality, safety and efficacy of JJAV-derived products, particularly when used in individuals 
with sensitivity towards these venom components. In this part of the PhD project, I 
identified IgE-binding components in JJAV, particularly those with a molecular weight of >20 
kDa. Additionally, I also aimed to correlate the IgE recognition of JJAV components to clinical 
data. I looked especially at the efficacy and tolerability/toxicity of this treatment modality, 
to establish if sub-groups of patients who recognised specific IgE-binding component(s) 
were more or less likely to experience side effects or therapeutic failure. 
 
5.2. Published manuscript 
A manuscript describing this work has been published in Clinical and Experimental Allergy. 
An electronic reprint is provided. 
 
T. Wanandy, R. Wilson, D. Gell, H.E. Rose, N. Gueven, N.W. Davies, S.G.A. Brown, M.D. 
Wiese. Towards complete identification of allergens in Jack Jumper (Myrmecia pilosula) ant 
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venom and their clinical relevance: An immunoproteomic approach. Clinical and 
Experimental Allergy. 2018; 48:1222-1234. (DOI: 10.1111/cea.13224)  
This article has been removed for 
copyright or proprietary reasons.
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5.3. Supporting information 
 
Supplementary Figure 1.   Representative profiles of reduced and alkylated JJAV components separated by 2-DE. The first dimension (IEF) was 
carried out in a non-linear pH 3–11 gradient IPG strip and the second dimension in a 4–12% Bis-Tris SDS-PAGE gel. (A) Second dimension gel 
was stained with SYPRO Ruby; (B) Second dimension gel was electro-transferred into a PVDF membrane and immunoblotted with a pooled 
sera from JJAV allergic patients. Areas marked in green and red show appearance of IgE-binding signals in non-reduced JJAV (loaded in the 
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marker well of the second dimension gel) and disappearance of IgE-binding signals due to reduction/alkylation reactions, respectively. 





Supplementary Figure 2.   Size Exclusion Chromatography profile of JJAV fractionation carried out in Superose® 12 column chromatography. 
Injections consisted of 0.5 mL of non-reduced JJAV at a concentration of 1 mg/mL. Elution was performed with 50 mM sodium phosphate, 150 
mM sodium chloride, pH = 7. Fractions of 0.5 mL were collected at a flow rate of 0.5 mL/min and eluents were detected by absorbance at 235 
nm. Molecular weight standards were thyroglobulin (TG, 670 kDa), γ-globulin (GG, 158 kDa), ovalbumin (OA, 44 kDa), myoglobulin (MB, 17 




Supplementary Figure 3.   Analysis of individual sera samples to determine clustering patterns in data. Data were normalised across rows and 
an unsupervised clustering (hierarchical clustering) was performed using a nonparametric Spearman’s rank correlation distance metric and 
average linkage clustering method. A heat-map expression image was created to visualise results. Heat-map colour configuration: grey, black, 
green, and red squares represent absence of data, unchanged, low (down-regulated), and high (up-regulated) relative expression, respectively. 
Colour intensity of every single square in the heat-map is directly associated with the intensity of measured value, score or category. Label of 
dendrogram in vertical direction: 3 digits number represents patient’s ID. Label of dendogram in horizontal direction: Reaction score describes 
patients’ reaction profile during VIT categorized numerically as described in Table 1; IDT = intradermal test; Reaction grade = severity of 





Supplementary Table 1.   Peptide evidence for the proteins reported in Table 1 
 
Band no Protein (Allergen) Protein ID Protein Accession Code Peptide Unique -10lgP Mass Length ppm m/z z RT Area Scan #Spec Start End PTM
5563 gi|815812192|ref|XP_012227043.1| R.HVGDLGNVEASADGVAK.V Y 75.14 1637.8009 17 0.7 819.9083 2 20.17 9.76E+05 1140 5 79 95
5563 gi|815812192|ref|XP_012227043.1| K.AVCVLQGEPVK.G N 60.48 1141.6165 11 1.9 571.8166 2 26.76 7.70E+04 1880 1 4 14
5563 gi|815812192|ref|XP_012227043.1| K.VTGEVSGLQK.G N 48.33 1016.5502 10 0.3 509.2825 2 16.98 2.05E+06 850 3 30 39
2 gi|749756765|ref|XP_011140861.1| K.YIQATDLSEASEEAVEEK.L Y 66.08 2010.9269 18 0.9 1006.4716 2 26.3 1.44E+05 1845 1 124 141
2 gi|749756765|ref|XP_011140861.1| R.DAAYDAFLEDLQK.G Y 60.27 1497.6987 13 2.8 749.8588 2 33.79 2.20E+05 2682 1 46 58
2 gi|749756765|ref|XP_011140861.1| K.MLYSSSFDALKK.S Y 59.23 1388.7009 12 1.4 695.3587 2 23.68 4.18E+04 1552 1 105 116
2 gi|749756765|ref|XP_011140861.1| K.MLYSSSFDALK.K Y 51.48 1260.606 11 0.8 631.3107 2 27.18 1.26E+04 1944 1 105 115
2 gi|749756765|ref|XP_011140861.1| K.M(+15.99)LYSSSFDALKK.S Y 51.03 1404.6959 12 0.2 703.3553 2 22.18 1.11E+04 1385 1 105 116 Oxidation (M)
2 gi|749756765|ref|XP_011140861.1| R.YVIFYIKDER.Q Y 46.43 1344.7078 10 1.6 673.3622 2 26.82 6.32E+04 1904 2 26 35
2 gi|749756765|ref|XP_011140861.1| R.QIDVEVIGPR.D Y 43.96 1124.6189 10 1.2 563.3174 2 24.9 2.29E+05 1687 1 36 45
11166 gi|951523050|ref|XP_014488366.1| K.ELNELYDEYAESK.G N 66.63 1601.7096 13 1.2 801.863 2 26.7 2.84E+05 1890 1 54 66
11166 gi|951523050|ref|XP_014488366.1| K.KEQGGLLGNFIK.W N 55.56 1302.7295 12 1 652.3727 2 25.91 4.02E+04 1801 1 122 133
11166 gi|951523050|ref|XP_014488366.1| K.EQGGLLGNFIK.W N 53.08 1174.6345 11 1.8 588.3256 2 29.56 2214 1 123 133
11166 gi|951523050|ref|XP_014488366.1| K.IDVNGDKTHPLWSYLK.K Y 41.43 1884.9734 16 1.1 629.3325 3 26.71 7.18E+04 1891 1 106 121
11166 gi|951523050|ref|XP_014488366.1| K.VKFDLFEK.I N 35.69 1024.5593 8 1.3 513.2876 2 25.35 1.89E+05 1737 1 98 105
Pilosulin 4 (Myr p 3) 11324 gi|51241753|dbj|BAD36780.1| K.ALADPESDAVGFADAVGEADPFDITK.L Y 75.92 2620.218 26 4.6 1311.1223 2 37.75 1.16E+05 3159 1 28 53
11165 gi|752896490|ref|XP_011266505.1| R.AGEGLIGLQAGTNK.G Y 54.48 1327.7096 14 0.4 664.8624 2 23.36 1.73E+04 1587 1 150 163
11165 gi|752896490|ref|XP_011266505.1| K.GATQAGQNFGATR.K Y 51.21 1277.6112 13 -0.5 639.8126 2 16.48 9.23E+03 850 1 164 176
11165 gi|752896490|ref|XP_011266505.1| K.MMDNLNQFQK.A Y 48.37 1267.569 10 -0.4 634.7915 2 23.22 6.15E+03 1571 1 73 82
11165 gi|752896490|ref|XP_011266505.1| R.SFTEEQLR.A Y 34.09 1008.4876 8 0.2 505.2512 2 19.56 8.75E+03 1162 1 142 149
11250 gi|749749329|ref|XP_011136874.1| R.VFFDMTADDKPVGR.I Y 92.57 1596.7606 14 1 799.3884 2 25.59 3.66E+05 1864 3 51 64
11250 gi|749749329|ref|XP_011136874.1| K.LTHTEPGILSMANAGPNTNGSQFFITSAK.T Y 69.41 3003.4761 29 2.5 1002.1685 3 29.87 2352 1 135 163
11250 gi|749749329|ref|XP_011136874.1| R.VFFDM(+15.99)TADDKPVGR.I Y 65.53 1612.7555 14 1.4 807.3862 2 22.46 3.97E+04 1527 3 51 64 Oxidation (M)
11250 gi|749749329|ref|XP_011136874.1| K.VVEGMDVVR.K Y 57.67 1002.5168 9 1 502.2662 2 21.02 8.65E+05 1371 1 177 185
11250 gi|749749329|ref|XP_011136874.1| F.FDMTADDKPVGR.I Y 49.98 1350.6238 12 2 676.3205 2 25.65 1.66E+04 1870 1 53 64
11250 gi|749749329|ref|XP_011136874.1| N.GSQFFITSAK.T Y 48.37 1084.5553 10 0.4 543.2852 2 23.56 4.16E+03 1639 1 154 163
11250 gi|749749329|ref|XP_011136874.1| R.KLEAMGSQSGK.T Y 45.71 1134.5703 11 0.7 568.2928 2 14.07 2.65E+05 765 1 186 196
11250 gi|749749329|ref|XP_011136874.1| K.LTHTEPGILSMAN.A Y 45.17 1382.6864 13 0.3 692.3507 2 25.24 2.28E+04 1824 1 135 147
11250 gi|749749329|ref|XP_011136874.1| N.AGPNTNGSQFFITSAK.T Y 43.38 1638.8002 16 -0.1 820.4073 2 24.73 5.86E+03 1767 1 148 163
11250 gi|749749329|ref|XP_011136874.1| K.VVEGM(+15.99)DVVR.K Y 38.15 1018.5117 9 0.2 510.2632 2 16.98 4.21E+04 974 1 177 185 Oxidation (M)
11250 gi|749749329|ref|XP_011136874.1| R.FEDENFK.L Y 38.12 927.3973 7 -0.1 464.7059 2 18.63 2.32E+04 1120 1 128 134
76 gi|730091|sp|Q07932.1|MYR1_MYRPI K.EAIPMAVEMAK.S Y 65.59 1188.5883 11 1.4 595.3022 2 25.57 4.18E+06 1861 1 94 104
76 gi|730091|sp|Q07932.1|MYR1_MYRPI K.EAIPMAVEM(+15.99)AK.S Y 62.95 1204.5831 11 0.5 603.2991 2 22.46 7.46E+05 1526 4 94 104 Oxidation (M)
76 gi|730091|sp|Q07932.1|MYR1_MYRPI K.EAIPM(+15.99)AVEM(+15.99)AK.S Y 54.96 1220.5781 11 -0.4 611.2961 2 19.95 6.49E+05 1256 1 94 104 Oxidation (M)
76 gi|730091|sp|Q07932.1|MYR1_MYRPI K.VM(+15.99)KEAIPMAVEMAK.S Y 40.77 1562.787 14 -0.6 782.4003 2 22.96 4.01E+03 1578 1 91 104 Oxidation (M)
76 gi|730091|sp|Q07932.1|MYR1_MYRPI K.EAIPM(+15.99)AVEMAK.S Y 37.33 1204.5831 11 -0.1 603.2988 2 23.03 1583 1 94 104 Oxidation (M)
76 gi|730091|sp|Q07932.1|MYR1_MYRPI K.VMKEAIPMAVEMAK.S Y 33.06 1546.7921 14 0 774.4033 2 24.71 3.90E+03 1765 1 91 104
Pilosulin 3a (Myr p 2) 14082 gi|1911818|gb|AAB50882.1| K.ALADPESDAVGFADAVGEADPIDWK.K Y 80.68 2558.1812 25 -0.2 1280.0975 2 36.8 3155 1 28 52
64 gi|751219056|ref|XP_011162596.1| R.MVELNADAPFCALYNDR.G Y 83.97 1940.876 17 4.1 971.4492 2 37.09 3442 1 31 47
64 gi|751219056|ref|XP_011162596.1| A.SVLVADTTM(+15.99)SR.M Y 61.31 1194.5914 11 0.7 598.3034 2 19.02 6.91E+04 1309 1 20 30 Oxidation (M)
64 gi|751219056|ref|XP_011162596.1| A.SVLVADTTMSR.M Y 59.95 1178.5966 11 1.7 590.3066 2 21.73 8.70E+05 1621 2 20 30
64 gi|751219056|ref|XP_011162596.1| R.IGASVLVADTTMSR.M Y 55.27 1419.7391 14 3 710.879 2 26.01 2108 1 17 30
64 gi|751219056|ref|XP_011162596.1| V.LVADTTMSR.M Y 51.47 992.4961 9 0.8 497.2557 2 17.82 1.58E+06 1172 1 22 30
64 gi|751219056|ref|XP_011162596.1| R.MVLGADPRK.V Y 50.25 985.5378 9 0.5 493.7765 2 17.19 2.35E+04 1109 1 53 61
64 gi|751219056|ref|XP_011162596.1| R.GVIQRMVLGADPR.K Y 41.53 1410.7765 13 -4.4 706.3924 2 28.96 1.67E+05 2458 1 48 60
64 gi|751219056|ref|XP_011162596.1| R.MVELNADAPF.C Y 40.59 1105.5114 10 3.1 553.7646 2 32.27 2.79E+04 2849 1 31 40









4 Peptidyl-prolyl cis-trans isomerase-
like
Pilosulin 1 (Myr p 1)






Band no Protein (Allergen) Protein ID Protein Accession Code Peptide Unique -10lgP Mass Length ppm m/z z RT Area Scan #Spec Start End PTM
64 gi|751219056|ref|XP_011162596.1| A.SVLVADTTMSR.M Y 50.74 1178.5966 11 1.4 590.3064 2 21.8 5.69E+05 1505 2 20 30
64 gi|751219056|ref|XP_011162596.1| A.SVLVADTTM(+15.99)SR.M Y 48.95 1194.5914 11 0.5 598.3033 2 19.09 7.33E+04 1197 1 20 30 Oxidation (M)
64 gi|751219056|ref|XP_011162596.1| R.NGYAEAVSDR.L Y 48.74 1080.4835 10 0.4 541.2493 2 17.25 5.46E+03 1020 1 199 208
64 gi|751219056|ref|XP_011162596.1| V.LVADTTMSR.M Y 42.49 992.4961 9 0.7 497.2556 2 17.89 2.76E+05 1076 1 22 30
64 gi|751219056|ref|XP_011162596.1| R.MVELNADAPF.C Y 37.57 1105.5114 10 3 553.7646 2 32.32 2.38E+04 2701 1 31 40
64 gi|751219056|ref|XP_011162596.1| V.LVADTTM(+15.99)SR.M Y 36.31 1008.491 9 0.1 505.2528 2 15.1 4.93E+04 844 1 22 30 Oxidation (M)
16696 gi|751221702|ref|XP_011164043.1| R.VIKDFMIQGGDFTK.G Y 57.66 1597.8174 14 1.6 799.9172 2 26.07 2.09E+04 1988 2 75 88
16696 gi|751221702|ref|XP_011164043.1| K.HYGAGWLSMANAGK.D Y 51.32 1461.6823 14 -0.9 731.8477 2 24.58 1.14E+04 1818 1 111 124
16696 gi|751221702|ref|XP_011164043.1| K.QTPWLDGR.H Y 40.12 971.4825 8 0.8 486.7489 2 22.5 1583 1 137 144
64 gi|751219056|ref|XP_011162596.1| R.IGASVLVADTTMSR.M Y 64.55 1419.7391 14 1 710.8776 2 25.95 1.39E+05 2108 1 17 30
64 gi|751219056|ref|XP_011162596.1| A.SVLVADTTM(+15.99)SR.M Y 56.69 1194.5914 11 1.1 598.3036 2 19.13 1328 1 20 30 Oxidation (M)
64 gi|751219056|ref|XP_011162596.1| A.SVLVADTTMSR.M Y 55.6 1178.5966 11 0.2 590.3057 2 21.83 2.13E+06 1639 1 20 30
64 gi|751219056|ref|XP_011162596.1| R.IGASVLVADTTM(+15.99)SR.M Y 47.06 1435.734 14 -2.5 718.8725 2 24.13 5.01E+04 1902 1 17 30 Oxidation (M)
18120 gi|826414896|ref|XP_012522151.1| K.DAGYTFDVAHTSVLTR.A Y 69.57 1751.8478 16 2.5 876.9333 2 27.1 2.94E+04 2198 3 47 62
18120 gi|826414896|ref|XP_012522151.1| K.YGEEQVQIWR.R Y 61.49 1306.6306 10 -0.3 654.3224 2 25.36 9.21E+04 2001 1 107 116
18120 gi|826414896|ref|XP_012522151.1| R.TLPYWNETIIPQLK.E Y 60.33 1714.9293 14 2.8 858.4743 2 33.55 7.11E+04 2951 1 164 177
18120 gi|826414896|ref|XP_012522151.1| K.AAMAAVAAQGK.A Y 59.31 987.5171 11 4.2 494.7679 2 16.51 1.72E+04 992 1 242 252
18120 gi|826414896|ref|XP_012522151.1| R.IIIAAHGNSLR.G Y 49.91 1163.6775 11 2.2 582.8473 2 19.13 1.36E+04 1295 1 182 192
18120 gi|826414896|ref|XP_012522151.1| R.YADGPKPEEFPK.F Y 45.07 1376.6611 12 2.5 689.3395 2 19.01 1.78E+04 1281 1 142 153
18120 gi|826414896|ref|XP_012522151.1| R.YADGPKPEEFPKFESLK.L Y 37.34 1980.9832 17 0.8 661.3355 3 24.39 3.84E+04 1892 1 142 158
135 gi|815804483|ref|XP_012222952.1| S.WDNELETIAQR.W Y 54.07 1373.6575 11 1.2 687.8369 2 26.66 1.50E+04 2158 1 102 112
135 gi|815804483|ref|XP_012222952.1| W.DNELETIAQR.W Y 52.42 1187.5782 10 1 594.797 2 23.68 8.53E+04 1820 1 103 112
6778 gi|752876495|ref|XP_011255648.1| R.LYASMHGIGTK.D Y 60.82 1176.5961 11 0 589.3053 2 19.45 2.63E+03 1286 1 261 271
6778 gi|752876495|ref|XP_011255648.1| R.LLVSLVQANR.D Y 56.09 1111.6713 10 0.4 556.8431 2 25.88 2002 1 158 167
6778 gi|752876495|ref|XP_011255648.1| R.QTFIEYEK.M Y 39.85 1056.5127 8 0.4 529.2639 2 22.44 1621 1 214 221
6778 gi|752876495|ref|XP_011255648.1| K.AIIDVLTKR.G Y 32.23 1027.6389 9 0.3 514.8269 2 24.27 3770 1825 1 43 51
23 gi|769852441|ref|XP_011637689.1| K.HEYHYTGQLSVPEPSTPGR.M Y 61.24 2154.0129 19 0.8 1078.0146 2 22.86 1.18E+04 1668 2 88 106
23 gi|769852441|ref|XP_011637689.1| K.FLGLWYVIQK.T N 58.82 1265.7172 10 3.4 633.868 2 34.37 1.96E+05 2964 1 40 49
23 gi|769852441|ref|XP_011637689.1| R.TLDQVQVDKIR.Q Y 48.53 1313.7302 11 -4.4 657.8695 2 20.25 3.12E+04 1376 1 156 166
8257 gi|826428058|ref|XP_012527752.1| R.NGGVPQEGDLKK.H N 61.61 1240.6411 12 2.4 621.3293 2 15.59 4.08E+06 964 2 99 110
8257 gi|826428058|ref|XP_012527752.1| K.HLEMFQK.H Y 57.17 931.4586 7 3.5 466.7382 2 18.58 1.56E+06 1318 2 111 117
9817 gi|795085211|ref|XP_011878235.1| K.YYVTIIDAPGHR.D Y 46.02 1403.7197 12 1.8 702.8684 2 23.8 6.58E+03 1727 1 85 96
9817 gi|795085211|ref|XP_011878235.1| R.LPLQDVYK.I Y 43.68 974.5436 8 0.2 488.2792 2 23.48 3.76E+04 1691 2 248 255
9817 gi|795085211|ref|XP_011878235.1| K.IGGIGTVPVGR.V Y 42.03 1024.6029 11 0.6 513.309 2 22.63 2.85E+04 1597 1 256 266
9851 gi|407021090|gb|AFS65405.1| R.LPLQDVYK.I Y 43.42 974.5436 8 0.1 488.2791 2 23.53 1.21E+04 1732 1 98 105
9851 gi|407021090|gb|AFS65405.1| K.IGGIGTVPVGR.V Y 41.15 1024.6029 11 1 513.3093 2 22.67 1.04E+04 1635 1 106 116
20912 gi|951526129|ref|XP_014467326.1| K.VSSTLSGLTGELK.G Y 60.98 1290.7031 13 0.8 646.3594 2 25.67 1.31E+04 1925 1 151 163
20912 gi|951526129|ref|XP_014467326.1| R.LGLTEYQAVK.E Y 53.1 1120.6128 10 0.6 561.314 2 22.97 2.76E+04 1632 1 330 339
20912 gi|951526129|ref|XP_014467326.1| R.GEHTEAEGGIYDISNK.R Y 52.67 1718.7747 16 1.4 860.3958 2 19.86 2.21E+03 1291 1 312 327
20912 gi|951526129|ref|XP_014467326.1| K.LIDDHFLFK.E Y 52.5 1146.6073 9 1.1 574.3116 2 27.28 9.01E+03 2106 1 180 188
20912 gi|951526129|ref|XP_014467326.1| R.LVTAVNEIEK.R Y 52.34 1114.6234 10 0.2 558.3191 2 21.42 1.84E+04 1462 1 245 254
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Band no Protein (Allergen) Protein ID Protein Accession Code Peptide Unique -10lgP Mass Length ppm m/z z RT Area Scan #Spec Start End PTM
22345 gi|769857915|ref|XP_011640613.1| K.IGNSLFDEEGAK.I N 44.63 1278.6091 12 0 640.3118 2 23.64 1.26E+04 1575 1 251 262
22345 gi|769857915|ref|XP_011640613.1| K.SLMDNVVEATTR.G Y 43.51 1334.65 12 2.1 668.3337 2 28.16 5.54E+04 2070 1 352 363
22345 gi|769857915|ref|XP_011640613.1| R.VDFNVPLK.E N 37.47 930.5175 8 0.4 466.2662 2 25.83 1807 1 22 29
22345 gi|769857915|ref|XP_011640613.1| R.IVAALDTVK.Y N 34.25 928.5593 9 1.2 465.2875 2 21.57 7.93E+03 1358 1 39 47
22345 gi|769857915|ref|XP_011640613.1| K.IVNDLLDK.A N 33.58 928.5229 8 0.3 465.2689 2 22.48 8260 1452 1 263 270
23704 gi|861647540|gb|KMQ95962.1| K.DEFGGVVVAVEK.Q Y 73.33 1247.6398 12 3.2 624.8292 2 28.04 3.32E+05 2149 1 338 349
23704 gi|861647540|gb|KMQ95962.1| R.YAEPPTGQQR.F N 61.75 1145.5465 10 -0.2 573.7804 2 15.54 2.93E+05 790 1 56 65
23704 gi|861647540|gb|KMQ95962.1| K.APGNLGLKDQVVALR.W N 61.35 1549.8939 15 0.8 775.9548 2 23.77 4.93E+04 1661 2 172 186
25219 gi|815803678|ref|XP_012222542.1| R.FFGLPVGVTPAVPTSENPANFR.Y Y 77.6 2316.1902 22 2.3 1159.105 2 34.54 4.66E+05 2737 2 252 273
25219 gi|815803678|ref|XP_012222542.1| K.LTAMGVLTDINNPEYSAR.E N 76.93 1963.9673 18 3.6 982.9944 2 30.86 4.12E+05 2329 1 154 171
25219 gi|815803678|ref|XP_012222542.1| K.LTAM(+15.99)GVLTDINNPEYSAR.E N 72.56 1979.9622 18 2.6 990.9909 2 28 1.03E+05 2010 1 154 171 Oxidation (M)
25219 gi|815803678|ref|XP_012222542.1| R.ELTQLGQLGENEK.A N 69.07 1457.7362 13 -0.3 729.8752 2 23.68 5.21E+05 1529 2 317 329
25219 gi|815803678|ref|XP_012222542.1| K.EADIVAVDPEDMYLAAK.N N 64.73 1848.8815 17 1.9 925.4498 2 31.72 7.60E+05 2424 1 70 86
25219 gi|815803678|ref|XP_012222542.1| K.TLAVAAPPVSPDEHLK.I Y 61.26 1643.8882 16 -0.2 822.9512 2 22.91 2.63E+05 1446 3 343 358
25219 gi|815803678|ref|XP_012222542.1| R.ALSTLFDKGCLVGR.W N 50.6 1478.7915 14 1.8 740.4044 2 29.53 1.49E+04 2182 1 177 190
25219 gi|815803678|ref|XP_012222542.1| R.NVLFKDDVK.E N 50.1 1076.5865 9 -0.7 539.3002 2 19.81 1.99E+05 1128 1 674 682
25219 gi|815803678|ref|XP_012222542.1| K.RFFGLPVGVTPAVPTSENPANFR.Y Y 49.15 2472.2913 23 3.9 825.1075 3 31.29 6.56E+04 2377 1 251 273
25219 gi|815803678|ref|XP_012222542.1| R.LFGAWDDKR.N N 48.83 1106.5509 9 0 554.2827 2 22.53 1.68E+05 1409 1 665 673
25219 gi|815803678|ref|XP_012222542.1| K.YMDVIER.N N 48.33 924.4375 7 0.4 463.2262 2 21.44 3.46E+05 1301 1 362 368
25219 gi|815803678|ref|XP_012222542.1| K.YM(+15.99)DVIER.N N 47.25 940.4324 7 3 471.2249 2 18.32 1.20E+04 987 1 362 368 Oxidation (M)
25219 gi|815803678|ref|XP_012222542.1| A.PPVSPDEHLK.I Y 46.95 1117.5768 10 0.6 559.796 2 23 6.18E+03 1456 1 349 358
25219 gi|815803678|ref|XP_012222542.1| K.DIMLLDEK.T N 45.04 975.4946 8 2.8 488.756 2 28.62 2.03E+05 2082 1 335 342
25219 gi|815803678|ref|XP_012222542.1| M.GVLTDINNPEYSAR.E N 43.68 1547.7579 14 0.9 774.8869 2 24.57 4.87E+03 1624 1 158 171
25219 gi|815803678|ref|XP_012222542.1| K.DLDINNVQGLR.G N 42.45 1255.6521 11 0.8 628.8338 2 27 1893 1 122 132
25219 gi|815803678|ref|XP_012222542.1| K.DIM(+15.99)LLDEK.T N 39.47 991.4896 8 0.7 496.7524 2 26.04 38200 1785 1 335 342 Oxidation (M)
25219 gi|815803678|ref|XP_012222542.1| L.AVAAPPVSPDEHLK.I Y 38.92 1429.7565 14 0.1 715.8856 2 22.99 1455 1 345 358
25219 gi|815803678|ref|XP_012222542.1| R.LFGAWDDK.R N 34.75 950.4498 8 0.7 476.2325 2 26.03 20900 1784 1 665 672
25219 gi|815803678|ref|XP_012222542.1| L.FGAWDDKR.N N 33.6 993.4668 8 0 497.7407 2 22.56 8.73E+03 1412 1 666 673
25219 gi|815803678|ref|XP_012222542.1| K.EADIVAVDPEDM(+15.99)YLAAK.N N 32.41 1864.8763 17 1.9 933.4472 2 28.71 24100 2092 1 70 86 Oxidation (M)
26382 gi|769837606|ref|XP_011629993.1| R.VYYLATAPGEPSQR.N N 73.81 1550.7728 14 2.3 776.3955 2 23.36 3.17E+06 1899 2 420 433
26382 gi|769837606|ref|XP_011629993.1| R.NLYSVPLDASQKPT.C N 53.5 1531.7882 14 0.8 766.902 2 25.16 3.11E+04 2105 1 434 447
26382 gi|769837606|ref|XP_011629993.1| K.MLFEIYR.N N 47.12 970.4946 7 2.5 486.2558 2 28.77 1.13E+06 2533 1 596 602
26382 gi|769837606|ref|XP_011629993.1| K.M(+15.99)LFEIYR.N N 44.45 986.4895 7 3.3 494.2537 2 26.46 1.04E+05 2255 2 596 602 Oxidation (M)
26382 gi|769837606|ref|XP_011629993.1| F.EYDHYITTNR.R Y 38.58 1310.5891 10 3.5 656.3041 2 23.12 1.56E+04 1871 1 568 577
77 gi|1911819|gb|AAB50883.1| K.EAIPMAVEMAKSQEEQQPQ Y 76.02 2142.9924 19 1.6 1072.5052 2 26.51 4.47E+04 2105 1 94 112
77 gi|1911819|gb|AAB50883.1| K.EAIPMAVEM(+15.99)AK.S Y 72.35 1204.5831 11 2.3 603.3002 2 22.51 5.30E+06 1612 2 94 104 Oxidation (M)
77 gi|1911819|gb|AAB50883.1| K.EAIPM(+15.99)AVEM(+15.99)AK.S Y 68.04 1220.5781 11 0.2 611.2964 2 20.03 8.67E+05 1325 2 94 104 Oxidation (M)
77 gi|1911819|gb|AAB50883.1| K.EAIPMAVEMAK.S Y 60.18 1188.5883 11 1.7 595.3024 2 25.52 6.74E+07 1981 2 94 104
77 gi|1911819|gb|AAB50883.1| K.EAIPM(+15.99)AVEMAK.S Y 57.66 1204.5831 11 2.1 603.3001 2 23.73 3.89E+06 1757 1 94 104 Oxidation (M)
77 gi|1911819|gb|AAB50883.1| K.VM(+15.99)KEAIPMAVEMAK.S Y 56.19 1562.787 14 2.2 782.4025 2 22.99 6.81E+04 1669 2 91 104 Oxidation (M)
77 gi|1911819|gb|AAB50883.1| A.IPMAVEMAK.S Y 55.17 988.5085 9 3.1 495.2631 2 25.62 1.29E+05 1995 1 96 104
34801 gi|161788856|dbj|BAF95069.1| K.AIKEILDCVIEK.G Y 70.03 1372.7635 12 3.2 687.3912 2 30.31 1.95E+05 2594 1 62 73
34801 gi|161788856|dbj|BAF95069.1| K.EILDCVIEK.G Y 48.95 1060.5474 9 2.4 531.2822 2 31.12 3.26E+05 2696 1 65 73
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Supplementary Table 2.   Correlation analysis of recognition of JJAV IgE-binding bands 
  
Calculated molecular weight of IgE-binding band (kDa) 
9 11–14 14-18  23–24  26 28 33 40–44 62 90 
IDT threshold  
r = -0.262 -0.271 -0.493 NS NS NS 0.210 NS NS NS 
P = 0.0137 0.0107 <0.0001    0.0491    
ImmunoCAP  
r = 0.270 0.486 0.564 NS NS NS -0.254 -0.224 -0.269 -0.263 
P = 0.0147 <0.0001 <0.0001       0.0221 0.0445 0.0154 0.0176 




Chapter 6: Development and preclinical evaluation of Jack Jumper ant Venom 
Immunotherapy with Advax™ adjuvant 
6.1. Introduction 
The relative difficulty in obtaining pharmaceutical grade ant venom extracts and the 
increase in demand to treat patients with JJAV allergy within Tasmania and interstate 
dictates the need to improvise our approach to treat future patients who are severely 
affected by this highly allergenic ant venom. In this part of the PhD project, I aimed to 
improve the safety and efficacy of JJA VIT by using lower doses of venom extracts combined 
with Advax™ adjuvant. Published clinical studies using Advax™ in combination with various 
vaccines (e.g. Hepatitis B, influenza, Japanese encephalitis virus, etc.) and more recently 
with Honeybee VIT (HB VIT) were very promising (321, 323, 326). Advax™ appears to exhibit 
a dual effect: (i) it modifies immune responses to provide a more protective effect by 
enhancing the production of antigen-specific IgG and in the HB VIT study it suppresses the 
production of allergen-specific IgE, and (ii) it exhibits a “dose-sparing” response allowing 
lower doses of antigen to be used (326, 345-347). Thus, I hypothesized that co-
administration of JJA VIT with Advax™ would improve the recognition and generation of a 
protective immune system response towards JJAV allergens and reduce the JJA VIT dose 
required to achieve the maintenance phase. Improving the immunogenicity of JJAV in the 
presence of Advax™ may potentially translate into reduced treatment side effects, assist 
with the “frequent reactors” to successfully achieve the treatment maintenance phase, and 
could overall reduce in JJAV requirements and production costs. In this part of my PhD 
project, I assessed the optimal formulation and physico-chemical and microbiological 
stability of JJA VIT with and without Advax™ stored in plastic syringes. Additionally, I 





6.2. Published manuscript 
A manuscript describing this work has been published in the Journal Pharmaceutical and 
Biomedical Analysis. An electronic reprint is provided. 
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6.3. Supporting information 
 
Supplementary Figure 1.   Representative chromatograms of JJAV samples containing (A) 100 μg/mL, (B) 50 μg/mL, (C) 25 μg/mL, and (D) 10 
μg/mL of venom protein. Samples were analysed using UPLC-UV coupled with Waters Acquity BEH C18 column and Photo Diode Array (PDA) 




Supplementary Figure 2.   SDS-PAGE analysis of venom components in JJAV (25 μg/mL) 
stored at 4oC (A) without Advax and (C) with Advax (10 mg/mL), or at 25oC (B) without Advax 
and (D) with Advax (10 mg/mL) for up to 7 days. Lanes: 1. Baseline, 2. After 2 hours, 3. After 




Supplementary Figure 3.   SDS-PAGE Immunoblot analysis of IgE binding venom 
components in JJAV (25 μg/mL) stored at 4oC (A) without Advax and (C) with Advax (10 
mg/mL), or 25oC (B) without Advax and (D) with Advax (10 mg/mL) for up to 7 days. Lanes: 
1. Baseline, 2. After 2 hours, 3. After 6 hours, 4. After 1 day, 5. After 2 days, 6. After 3 days, 




Supplementary Figure 4.   Effects of Advax (10 mg/mL) and storage temperature (4oC or 
25oC) on the buffering capacity of phosphate buffered saline in JJAV diluent used in the 
formulation of JJAV (25 μg/mL) with or without Advax. Analysis of pH was taken from each 










































































Supplementary Figure 5.   Effects of Advax (10 mg/mL) and storage temperature (4oC or 
25oC) on benzyl alcohol concentration in JJAV diluent used in the formulation of JJAV (25 
μg/mL) with or without Advax. Benzyl alcohol concentration in the samples was quantified 
against an analytical standard using UPLC-UV. Analysis was calculated as a percentage 
relative to baseline samples. Quadruple analysis was performed on each sample and 




Supplementary Table 1.   Allergenic potency of various JJAV concentrations with or without 








Allergenic Potency as 50% Inhibition 




– 0.349 ± 0.072 
0.60 
+ 0.385 ± 0.081 
25oC 
– 0.501 ± 0.061 
0.43 
+ 0.424 ± 0.138 
10 µg/mL 
4oC 
– 0.301 ± 0.002 
0.99 
+ 0.304 ± 0.230 
25oC 
– 0.276 ± 0.065 
0.66 
+ 0.335 ± 0.204 
1 µg/mL 
4oC 
– 0.648 ± 0.316 
0.35 
+ 0.441 ± 0.113 
25oC 
– 0.480 ± 0.230 
0.27 
+ 0.291 ± 0.114 
0.1 µg/mL 
4oC 
– 0.297 ± 0.007 
0.06 
+ 0.628 ± 0.118 
25oC 
– 0.224 ± 0.001 
0.10 
+ 0.461 ± 0.116 




Supplementary Table 2.   Concentration of Myr p allergens at baseline in formulations 







AUC at Baseline  
(Mean ± SD)  
4oC 
– 
Myr p 1 3039.22 ± 84.95 
Myr p 2 9421.88 ± 322.82 
Myr p 3 378.76 ± 23.26 
+ 
Myr p 1 3151.46 ± 161.53 
Myr p 2 9730 ± 541.86 
Myr p 3 392 ± 43.71 
25oC 
– 
Myr p 1 3249.23 ± 102.43 
Myr p 2 9757.38 ± 412.2 
Myr p 3 415.93 ± 11.21 
+ 
Myr p 1 3179.17 ± 131.13 
Myr p 2 9673.43 ± 257.06 




Supplementary Table 3.   Endotoxin level in multiple batches of JJA VIT, JJAV diluents and 





Mean ± SD 
(EU/mL) 
JJA VIT 5 0.028 ± 0.001 
JJAV diluent 5 0.022 ± 0.001 
Advax 
adjuvant 




Supplementary Table 4.   Antimicrobial efficacy of benzyl alcohol in JJAV diluent used in the formulation of JJAV (25 μg/mL) with or without 








1 ± 1 x 106 CFU/plate 4 ± 1 x 105 CFU/plate 3 ± 3 x 105 CFU/plate 1 x 105 to 1 x 106 CFU/plate on initial count
JJAV 5 Log reduction






5 Log reduction on both 
sample types





≥ 1 log reduction from the initial count 
≥ 3 log reduction from the initial count 
No increase from the 14 day count
Acceptance criterion
Observed Log reduction (Mean of 5 plates)
6 Log reduction on both 
sample types
6 Log reduction on both 
sample types
6 Log reduction on both 
sample types
5 Log reduction on both 
sample types
5 Log reduction on both 
sample types
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Chapter 7: General discussion 
 
7.1. Optimising the delivery of Jack Jumper ant Venom Immunotherapy 
I performed the first published study to assess the consistency of Hymenoptera venom 
allergen extracts and the impact of environmental factors on extract quality (see Chapter 4 
for details of this research). My analysis of the 17 batches of purified M. pilosula venom 
extracts in the form of Active Pharmaceutical Ingredients found good batch-to-batch 
consistency. This finding reinforces our manufacturing requirements for pooling venom sacs 
obtained from different collection times and locations. In this study, I also observed that the 
relative amounts of Myr p 3 (Pilosulin 4.1) allergens and endotoxin concentration are two 
intrinsic factors that may affect the total allergenic potency in M. pilosula venom extracts. In 
addition, prolonged storage above room temperature and contact with rubber stoppers are 
two environmental factors that impact the amounts of Myr p peptides in venom extracts. 
Furthermore, prolonged exposure of venom extracts to temperatures above 40oC affects 
the protein >20 kDa with IgE-binding activity. These results strongly support our current 
protocol to store collected ants, dissected venom sacs and venom extracts at ultra-low 
temperature (‒20oC or below). This requirement will control bio-burden level (and hence 
endotoxin concentration) and the preservation of allergenic components and allergenic 
potency in venom extracts. A protocol for storing vials containing M. pilosula venom 
extracts in an upright position will limit the adsorption of allergenic components into rubber 
stoppers. These requirements are important to maintain the diagnostic utility of intradermal 
testing reagents and efficacy of Allergen Immunotherapy products (348), and the data 
generated from this study have been collated into published guidelines for the storage, 
handling and transport of M. pilosula venom extracts for practicing clinicians (349). 
 Using serum samples from patients with clinically diagnosed allergy to M. pilosula 
venom, I confirmed previous observations (11, 174), which reported that a number of high 
molecular weight proteins >20 kDa in M. pilosula venom are capable of binding to IgE. 
Importantly, my analysis showed that some of these proteins are recognized by the immune 
system in a considerable number of patients who are allergic to M. pilosula venom (see 
Chapter 5 for details of this research). My observation that these proteins are susceptible to 
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elevated temperature, which potentially affects quality, safety and efficacy of our Allergen 
Immunotherapy products and thus patients care, further justifies the need to identify these 
venom components. Separation of proteins in native venom from the more abundant Myr p 
peptides by Size Exclusion Chromatography followed by SDS-PAGE, immunoblot and tandem 
mass spectrometry enabled me to establish the identity of the venom proteins with and 
without IgE-binding properties. Classical (e.g. phospholipase A2, hyaluronidase, venom 
allergen 3, and venom dipeptidyl peptidase IV), and non-classical (e.g. peptidyl-prolyl cis-
trans isomerase, phosphoglycerate mutase, and arginine kinase) Hymenoptera venom 
proteins were identified in M. pilosula venom (see Chapter 5 for details of this research). 
Most of the newly identified IgE-binding proteins were enzymes, two of which, arginine 
kinase and dipeptidyl peptidase IV, were glycosylated. My analysis identified a positive 
correlation between recognition to Myr p 1 and a risk of developing adverse reaction to 
immunotherapy, and a negative correlation between IgE-binding recognition to high 
molecular weight venom proteins and low-titre reading of venom-specific IgE by 
ImmunoCAP. This study has for the first time established the complete identity of IgE-
binding components in M. pilosula venom and their clinical relevance. 
Adjuvants are commonly used for their antigen-sparing effect in vaccines and an 
increasing number of Allergen Immunotherapy products formulated with an adjuvant 
system are clinically available (306, 310). There is an enormous potential for a safer, more 
effective Venom Immunotherapy product that utilizes less of the valuable venom extracts 
compared to current products. Previous attempts to formulate M. pilosula Venom 
Immunotherapy with the adjuvant L-tyrosine revealed the difficulty of incorporating 
allergenic materials and maintaining their stability in an adjuvant system (350). In the 
current study, the incorporation of delta inulin (Advax™) adjuvant into a low-dose M. 
pilosula Venom Immunotherapy formulation only marginally affected the physicochemical 
and microbiological stability of the allergen product components for at least 2 days at 4 and 
25oC. Importantly, similar results were obtained in products formulated without the 
adjuvant. In vivo studies in mice showed that low-dose M. pilosula Venom Immunotherapy 
formulated with Advax™ adjuvant significantly increased venom-specific IgG, consistent 
with an antigen-sparing effect of the adjuvant (see Chapter 6 for details of this research). 
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These encouraging results observed in this preclinical study provide supportive data to 
clinically test Advax™ adjuvant in combination with low-dose M. pilosula Venom 
Immunotherapy (Clinical Trial Notification ID: CT-2015-CTN-03308-1 v2; Human Research 
Ethics Committee approvals: H0015893 and HREC/15/RAH/438, for the Royal Hobart 
Hospital and Royal Adelaide Hospital, respectively). 
 
7.2. Conclusion 
My PhD research has advanced our current understanding on the manufacture, 
storage and shelf-life of Allergen Immunotherapy products derived from purified M. pilosula 
venom extracts, and the complete identity and clinical relevance of immunologically active 
components in the venom. Importantly, the results from this study have provided us with 
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